Introduction {#s1}
============

Transcription by RNA polymerase III (Pol III) is regulated by MAF1, which is a highly conserved protein in eukaryotes ([@bib28]; [@bib30]). MAF1 represses Pol III transcription through association with BRF1, a subunit of initiation factor TFIIIB, which prevents attachment of TFIIIB onto DNA. This interaction also inhibits Pol III from binding to BRF1, which in turn prevents recruitment of Pol III to Pol III promoters. Furthermore, MAF1 also inhibits Pol III transcription through direct binding with Pol III, which interferes with the recruitment of Pol III to the assembled TFIIIB/DNA complexes ([@bib11]; [@bib35]). In addition, association of MAF1 with Pol III-transcribed genes has been detected genome-wide concomitant with an increase in occupation during repression; this indicates that direct interaction of MAF1 with Pol III genes is also an important attribute of repression ([@bib31]).

MAF1 has also been proposed to have the potential to repress Pol II-mediated transcription via repression of *TBP* transcription due to binding of MAF1 to the Elk-1 site on the *TBP* promoter ([@bib18]). Thus, to investigate the potential regulatory role of MAF1 in Pol II genes, we carried out *MAF1* knockdown coupled with microarray analysis. Microarray analysis showed that 124 genes were upregulated and 170 genes were downregulated more than twofold after *MAF1* knockdown. Ingenuity Pathway Analysis (IPA) indicated that most of these genes are related to cell proliferation. Among them, *CDKN1A* (also known as p21) was significantly upregulated and the mechanism of induced transcription of this gene after *MAF1* knockdown was further investigated.

*CDKN1A* is a cyclin-dependent kinase inhibitor that inhibits cell cycle progression through interaction with cyclins and cyclin-dependent kinases (CDKs). As a member of the Cip and Kip family of CDK inhibitors, *CDKN1A* mediates p53-dependent cell-cycle arrest at the G~1~ phase by inhibiting the activity of *CDK2* and *CDK1* (also known as *CDC2*). In addition, *CDKN1A* also inhibits the activity of proliferating cell nuclear antigen and blocks DNA synthesis and repair as well as cell-cycle progression. As a result, *CDKN1A* can regulate many cellular processes, such as proliferation, differentiation, apoptosis, metastasis, cell survival, and stem cell renewal. Expression of *CDKN1A* can be regulated at the transcriptional level by oncogenes and tumor suppressor proteins that bind various transcription factors to specific elements in response to a variety of intracellular and extracellular signals ([@bib1]; [@bib37]).

In this study, we showed that MAF1 can bind to the *CDKN1A* promoter to repress its transcription. Enhanced binding of Pol III after *MAF1* knockdown induced *CDKN1A* transcription and chromatin looping by recruiting common Pol II and Pol III transcription factors as well as binding of TBP, p300, CFP1, and PCAF, along with increase in histone modifications associated with gene activation. Simultaneous knockdown of Pol III and *MAF1* abolished both promoter looping and activation of *CDKN1A* transcription, which indicates that Pol III actively participated in regulation of Pol II genes. Similar results were observed in another cell proliferation-related gene, *GDF15*. These observations reveal a new type of gene regulation in which binding of MAF1 regulates Pol III-mediated transcriptional activation and chromatin looping of Pol II genes.

Results {#s2}
=======

*MAF1* knockdown strongly upregulated *CDKN1A* expression {#s2-1}
---------------------------------------------------------

To examine whether MAF1 has the potential to repress Pol II-transcribed genes, we first examined the knockdown effect of *MAF1* by quantitative RT-PCR (qRT-PCR) and immunoblot using multiple siRNAs ([Figure 1A,B](#fig1){ref-type="fig"}). The siRNA with the strongest knockdown effect was used to perform expression analysis using microarray. 124 Pol II-transcribed genes were upregulated more than twofold after *MAF1* knockdown. Among them, *CDKN1A* was significantly upregulated, resulting in the downregulation of positive cell cycle regulators. Consistent with expression data, flow cytometry analysis showed that *MAF1* knockdown arrested cells at the G~1~ phase ([Figure 1C](#fig1){ref-type="fig"}). We carried out qRT-PCR to confirm whether *CDKN1A* expression was upregulated by *MAF1* knockdown. Efficiency of *MAF1* knockdown was verified by the strong upregulation of two products of Pol III, pretRNA^Tyr^ and pretRNA^Leu^ ([@bib30]) ([Figure 1D](#fig1){ref-type="fig"}). Consistent with microarray analysis, qRT-PCR and immunoblot analysis showed that *CDKN1A* expression was upregulated about 10-fold after *MAF1* knockdown ([Figure 1D,E](#fig1){ref-type="fig"}). *GAPDH*, *ACTB*, and *TAF5*, genes that were not affected by *MAF1* knockdown in the microarray, were chosen as the control for qRT-PCR. Expression of these genes was not affected by *MAF1* knockdown ([Figure 1D](#fig1){ref-type="fig"}).10.7554/eLife.06283.003Figure 1.*MAF1* knockdown strongly upregulates *CDKN1A* expression and arrests MCF-7 cells at the G~0~/G~1~ phase.Analysis of *MAF1* expression after *MAF1* knockdown using three different siRNAs in MCF-7 cells by quantitative RT-PCR (**A**) and immunoblot analysis (**B**). The immunoblot results were quantified (left panel) using α-tubulin as a loading control on a representative gel (right panel). (**C**) *MAF1* knockdown arrested the MCF-7 cell cycle at the G~0~/G~1~ phase. At 72 hr after knockdown, cells were stained with propidium iodide and subjected to cell cycle analysis by flow cytometry (top panel). The quantification results show that *MAF1* knockdown increased cells arrested at the G~0~/G~1~ phase by 16.4% ± 1.76% (bottom panel). (**D**) Quantitative RT-PCR of genes in MCF-7 cells subjected to siRNA knockdown for 72 hr. *CDKN1A* expression was upregulated 10-fold, and upregulation was abolished by double knockdown of *MAF1* and *POLR3A*. Relative expression normalized to *GAPDH* is displayed. (**E**) Immunoblot analysis of *CDKN1A* expression after *MAF1* knockdown in MCF-7 cells. The results were quantified (left panel) using α-tubulin as a loading control on a representative gel (right panel). All data shown represent mean ± SD, *n* ≥ 3, \*\*p \< 0.01, \*\*\*p \< 0.001 (*t*-test).**DOI:** [http://dx.doi.org/10.7554/eLife.06283.003](10.7554/eLife.06283.003)10.7554/eLife.06283.004Figure 1---figure supplement 1.*MAF1* knockdown upregulates *CDKN1A* and *GDF15* expression in HCT116^p53+/+^ (wild-type), HCT116^p53−/−^ (p53-null), MCF-10A, and MDA-MB-231 cell lines.(**A**) Immunoblot analysis of p53 expression in wild-type and p53-null HCT116. Quantitative RT-PCR of genes in HCT116 wild-type (**B**) and HCT116^p53−/−^ (**C**) cells subjected to siRNA knockdown for 72 hr. (**D**) Immunoblot analysis of *MAF1*, *CDKN1A*, and p53 expression in p53-null HCT116 subjected to *MAF1* knockdown. Quantitative RT-PCR of genes in MCF-10A (**E**) and MDA-MB-231 (**F**) cells subjected to siRNA knockdown for 72 hr. Expression of *CDKN1A* and *GDF15* was upregulated independent of p53 after *MAF1* knockdown. *POLR3A* expression analysis after *POLR3A* knockdown using three different siRNAs in MCF-7 cells by quantitative RT-PCR (**G**) and immunoblot analysis (**H**). The results were quantified (left panel) using α-tubulin as a loading control on a representative gel (right panel). Relative expression normalized to *GAPDH* is displayed for all quantitative RT-PCR. All data shown represent mean ± SD, *n* = 3, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 (*t*-test).**DOI:** [http://dx.doi.org/10.7554/eLife.06283.004](10.7554/eLife.06283.004)

Because *CDKN1A* is a downstream target of p53 ([@bib3]), we further performed *MAF1* knockdown in HCT116^p53+/+^ (wild-type) and HCT116^p53−/−^ (p53-null) cell lines to analyze whether the induced *CDKN1A* expression is dependent on p53. The absence of p53 in HCT116^53−/−^ was confirmed by immunoblot ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). *CDKN1A* expression was induced after *MAF1* knockdown in both wild-type and p53-null HCT116, which indicates that the activation is independent of p53 ([Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}). Immunoblot analysis also showed that *CDKN1A* protein level was upregulated after *MAF1* knockdown in p53-null HCT116 ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). *CDKN1A* activation by *MAF1* knockdown was also found in a non-tumorigenic cell line (MCF-10A) and a p53 mutant breast cancer cell line (MDA-MB-231) ([Figure 1---figure supplement 1E,F](#fig1s1){ref-type="fig"}). Together, these results demonstrate that MAF1 can regulate *CDKN1A* expression in a variety of cell types independent of p53.

*CDKN1A* activation after *MAF1* knockdown could be due either to interference of binding of transcription factors to the *CDKN1A* promoter by MAF1 or to the active recruitment or activation of Pol III after *MAF1* knockdown. To determine which of these two mechanisms are involved in this process, we carried out simultaneous knockdown of both *MAF1* and Pol III. The former mechanism would not be affected by the double knockdown, whereas the latter would be. The effect of Pol III knockdown was analyzed by qRT-PCR and immunoblot using multiple siRNA sequences ([Figure 1---figure supplement 1G,H](#fig1s1){ref-type="fig"}). Simultaneous knockdown of Pol III and *MAF1* indeed abolished the induction of *CDKN1A* expression by knockdown of only *MAF1* ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B,C,E,F](#fig1s1){ref-type="fig"}) in five different cell lines. A control experiment using two Pol III genes, pretRNA^Tyr^ and pretRNA^Leu^, confirmed the efficiency of Pol III knockdown ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B,C,E,F](#fig1s1){ref-type="fig"}). Knockdown of Pol III alone did not significantly affect *CDKN1A* expression ([Figure 1D](#fig1){ref-type="fig"}). This result indicates that Pol III plays a critical role in activation of *CDKN1A* expression by *MAF1* knockdown.

Because mRNA levels can be affected by transcription, post-transcriptional processing as well as RNA turnover rate, upregulation of gene expression after *MAF1* knockdown could be due to post-transcriptional mechanisms other than transcription activation. To demonstrate that the induced *CDKN1A* expression indeed occurs at the transcriptional level, we analyzed the rate of nascent transcription by conducting a nuclear run-on experiment after *MAF1* knockdown or simultaneous knockdown of *MAF1* and Pol III. The run-on nascent RNA was labeled with biotin, affinity purified, and analyzed by RT-PCR. A negative control without biotin labeling was used. Consistent with qRT-PCR analysis, nascent transcription of *CDKN1A* was indeed induced after *MAF1* knockdown, whereas transcription of *ACTB* and *TAF5* was not affected ([Figure 2A,B](#fig2){ref-type="fig"}). Simultaneous knockdown of *MAF1* and Pol III diminished the induced nascent RNA transcription of *CDKN1A* by knockdown of *MAF1* alone ([Figure 2A,B](#fig2){ref-type="fig"}). These results indicate that Pol III is required for the induction of *CDKN1A* upon MAF1 knockdown.10.7554/eLife.06283.005Figure 2.*MAF1* knockdown upregulates *CDKN1A* at the transcriptional level.(**A**) For run-on assay, MCF-7 cells were subjected to siRNA knockdown of *MAF1* (KD MAF) or simultaneous knockdown of *MAF1* and Pol III for 72 hr (KD P/M). Nuclei were prepared, and a run-on reaction was performed. Run-on biotin-labeled newly transcribed RNA (Run-on) was affinity purified and subjected to RT-PCR (left panel). Input indicates total RNA before affinity purification, and a negative control was performed by omitting biotinylated nucleotides and subjected to RT-PCR (right panel). (**B**) The run-on results were quantified, and the data shown represent mean ± SD, *n* = 3, \*p \< 0.05, \*\*p \< 0.01 (*t*-test). (**C**) Schematic diagram of the *CDKN1A* promoter, including locations of exon 1 (black rectangle), SINE (MIR3), CpG island (green rectangle), guanine-cytosine (GC) skew, and R-loop foot-printing region (blue rectangle). (**D**) Each vertical black line indicates the position of a cytosine on the sense DNA strand. (**E**) Analysis of R-loop foot-printing was performed by native sodium bisulfite treatment followed by PCR amplification and cloning. A total of at least 10 clones were obtained for each knockdown condition (knockdown control, 'KD Ctrl'; knockdown *MAF1*, 'KD MAF1'; and simultaneous knockdown of *MAF1* and Pol III, 'KD MAF1/Pol III'). Each vertical red line represents a converted cytosine to thymine in the sense direction (*CDKN1A* mRNA) for the knockdown control, knockdown *MAF1*, and simultaneous knockdown of *MAF1* and Pol III. Percentage indicates how many clones at a particular cytosine were converted. Knockdown *MAF1* extended the length of R-loop formation in *CDKN1A*, whereas simultaneous knockdown of *MAF1* and Pol III abolished the extension. This indicates that regulation of *CDKN1A* expression by MAF1 and Pol III occurs at the transcriptional level. Background conversion (approximately 5% of cytosine) may be seen because of DNA breathing during the prolonged incubation at 37°C in our data and data produced by others ([@bib38]). (**F**) Schematic diagram of *ACTB*, including locations of exons, CpG island, GC skew, and R-loop foot-printing region. (**G**) Each vertical black line indicates the position of a cytosine on the sense DNA strand. (**H**) Each vertical red line represents a converted cytosine to thymine in the sense direction (*ACTB* mRNA) for knockdown control and knockdown *MAF1*. Knockdown *MAF1* did not affect the length of R-loop in *ACTB*, which correlates with the expression data from [Figure 1A](#fig1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.06283.005](10.7554/eLife.06283.005)

R-looping analysis indicated that expression of *CDKN1A* is regulated by MAF1 and Pol III at the transcriptional level {#s2-2}
----------------------------------------------------------------------------------------------------------------------

Recent evidence indicated that R-loop formation positively correlates with active transcription in human cells by maintaining the unmethylated state at promoters with skewed guanine-cytosine (GC) content ([@bib13]). The high GC skew of the *CDKN1A* promoter prompted us to test whether the R-loop was present in this region during the activation of transcription by *MAF1* knockdown ([Figure 2C](#fig2){ref-type="fig"}). We performed R-loop foot-printing by native sodium bisulfite treatment, which converts cytosine to uracil only on the single-stranded DNA ([@bib38]). *MAF1* knockdown resulted in the formation of the extended R-loop in the gene body of *CDKN1A*, which indicates active transcription, whereas simultaneous knockdown of Pol III and *MAF1* inhibited R-loop formation ([Figure 2C--E](#fig2){ref-type="fig"}). The R-looping of the control gene *ACTB*, an active housekeeping gene with high GC skew and expression, was not affected by *MAF1* knockdown ([Figure 2F--H](#fig2){ref-type="fig"}). The results of R-loop formation and nuclear run-on described above further confirmed that the upregulation of *CDKN1A* expression by *MAF1* knockdown and recruitment of Pol III occurred at the transcriptional level.

*MAF1* knockdown enhanced binding of Pol III and Pol II at the *CDKN1A* promoter {#s2-3}
--------------------------------------------------------------------------------

Expression analysis indicated that *CDKN1A* expression is strongly upregulated after *MAF1* knockdown, and simultaneous knockdown of *MAF1* and Pol III diminished the induced expression. These results indicate that removal of *MAF1* may induce recruitment of Pol II and Pol III to activate transcription. To examine this possibility, chromatin-immunoprecipitation (ChIP) analysis followed by quantitative PCR (qPCR) was performed under various knockdown conditions. Efficiency of *MAF1* or Pol III knockdown as well as simultaneous knockdown of *MAF1* and Pol III was verified by the binding of Pol III to pretRNA^Arg^ and pretRNA^Leu^ genes. The results showed enhanced binding of Pol III at pretRNA^Arg^ and pretRNA^Leu^ after *MAF1* knockdown, and the binding was diminished after double knockdown ([Figure 3A,B](#fig3){ref-type="fig"}). Examination of *CDKN1A* gene in the UCSC Genome Database shows that there are two transcription start sites, NM_001220777 (long form) and NM_001220778 (short form), which are 2.25 kb apart ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Although the expression of both forms was induced after *MAF1* knockdown, the short form had higher expression level and stronger promoter activity in the MCF-7 cell line ([Figure 3---figure supplement 1B--D](#fig3s1){ref-type="fig"}). ChIP analysis showed that MAF1 was associated with both transcription start site regions ([Figure 3C,D](#fig3){ref-type="fig"}). Furthermore, *MAF1* knockdown resulted in the depletion of this regulatory factor with concomitant increase in the binding of both Pol II and Pol III polymerases to both transcription start site regions ([Figure 3E,F](#fig3){ref-type="fig"}).10.7554/eLife.06283.006Figure 3.*MAF1* knockdown enhanced binding of Pol III and Pol II at the *CDKN1A* promoter.ChIP was performed in MCF-7 cells subjected to siRNA knockdown for 72 hr. DNA isolated from immunoprecipitated chromatin was subjected to qPCR and calculated as indicated in the 'Materials and methods'. Significant binding of Pol III was detected at two tRNA genes, tRNA^Arg^ (**A**) and tRNA^Leu^ (**B**), after *MAF1* knockdown (KD MAF1). The enhance binding of Pol III was diminished when there was simultaneous knockdown of *MAF1* and Pol III (KD M/Pol III). (**C**) Diagram of the *CDKN1A* promoter, including locations of exon 1 (long form: L-Ex1, and short form: Ex1), SINEs (AluSx and MIR3), and ChIP--qPCR amplicons (p21-L, p1, p2, and p3). (**D**) Binding of MAF1 was detected at the *CDKN1A* promoter, which diminished after *MAF1* knockdown. (**E**) Enhanced binding of Pol III was detected at the *CDKN1A* promoter after *MAF1* knockdown. (**F**) *MAF1* knockdown indicates enhanced binding of Serine-5-phosphorylated Pol II, which was abolished when there was simultaneous knockdown of Pol III and *MAF1*. (**G**) Enhanced binding of BRF1 was detected at the *CDKN1A* promoter after *MAF1* knockdown. (**H**) Top panel: diagram of the *ACTB* promoter, including locations of each exon (Ex1 to Ex4) and ChIP--qPCR amplicons (p1, p2, and p3). Bottom panel: neither MAF1 nor Pol III was detected at the *ACTB* promoter. Only binding of Pol II was detected at the *ACTB* promoter. (**I**) Top panel: diagram of the *TAF5* promoter, including locations of exon 1 and ChIP--qPCR amplicons (p1, p2, and p3). Bottom panel: neither MAF1 nor Pol III was detected at the *TAF5* promoter. Only binding of Pol II was detected at the *TAF5* promoter. All data shown represent the mean ± s.e.m., *n* ≥ 3, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 (*t*-test).**DOI:** [http://dx.doi.org/10.7554/eLife.06283.006](10.7554/eLife.06283.006)10.7554/eLife.06283.007Figure 3---figure supplement 1.Expression and promoter activity of *CDKN1A* transcripts in the MCF-7 cell line.(**A**) Representative diagram of NM_001220777 (CDKN1A-L, long form) and NM_001220778 (CDKN1A-S, short form). (**B**) cDNA samples used in [Figure 1C](#fig1){ref-type="fig"} were used to analyze *CDKN1A* transcript expression. Expression of CDKN1A-S was measured relative to that of CDKN1A-L. (**C**) Expression of both *CDKN1A* transcripts was upregulated after *MAF1* knockdown, and the upregulation was abolished by simultaneous knockdown of *MAF1* and Pol III. A relative expression normalized over *GAPDH* is displayed. (**D**) CDKN1A-L and CDKN1A-S promoter regions were constructed and cloned into a pGL3-basic reporter plasmid, as indicated in the 'Materials and methods'. Luciferase reporter assays were performed in MCF-7 cells, and the results were normalized with those for β-galactosidase. Promoter activity was measured relative to CDKN1A-L. All data shown represent mean ± SD, *n* ≥ 3, \*p \< 0.05, \*\*p \< 0.01 (*t*-test).**DOI:** [http://dx.doi.org/10.7554/eLife.06283.007](10.7554/eLife.06283.007)

Consistent with the expression data, there was significant increase in the binding of active, Serine-5-phosphorylated Pol II at the *CDKN1A* promoter after *MAF1* knockdown, which indicates that the gene was in the active transcription state. The binding of active Pol II was abolished after simultaneous knockdown of Pol III and *MAF1* ([Figure 3F](#fig3){ref-type="fig"}). Simultaneous knockdown of *MAF1* and *BRF1*, a subunit of TFIIIB that associates with Pol III and is required for binding of Pol III to the DNA template, also abolished the enhanced binding of Pol III and Pol II after *MAF1* knockdown ([Figure 3E,F](#fig3){ref-type="fig"}). ChIP analysis also indicated induced binding of BRF1 after *MAF1* knockdown, whereas the binding was diminished under simultaneous knockdown of either Pol III or *BRF1* with *MAF1* ([Figure 3G](#fig3){ref-type="fig"}). These results therefore support the mechanism that recruitment of Pol III to the promoter after *MAF1* knockdown enhances *CDKN1A* expression. Expression of *ACTB* and *TAF5* was not affected because MAF1 and Pol III did not bind to their promoters ([Figure 3H,I](#fig3){ref-type="fig"}) and their expression was not affected by *MAF1* knockdown; therefore, they were used as negative controls. The transcription of these two control genes was not affected by single or double knockdown of Pol III and/or *MAF1* ([Figure 1D](#fig1){ref-type="fig"}).

MAF1 binds to the short interspersed element (SINE) of *CDKN1A* {#s2-4}
---------------------------------------------------------------

Because ChIP data revealed that MAF1 may directly bind to the promoter, we searched for potential binding sites in the *CDKN1A* promoter region. We noticed a MIR3 element (a SINE with Pol III promoter) that could be transcribed by Pol III and therefore might represent the target-binding site of MAF1. To test this possibility, we used an in vitro DNA binding reaction ([@bib5]; [@bib34]) to examine whether purified MAF1 protein could bind to the cloned *CDKN1A* promoter. Consistent with ChIP, in vitro DNA binding assay showed that purified MAF1 protein could indeed bind to the *CDKN1A* promoter that contained the MIR3 element ([Figure 4A,B](#fig4){ref-type="fig"}), but the binding was abolished when the MIR3 repeat element was deleted, which indicates specificity of MAF1 binding to the MIR3 element ([Figure 4A,B](#fig4){ref-type="fig"}). To further show that the Pol III promoter of the MIR3 element is responsible for the binding, an in vitro binding assay was carried out with DNA in which the MIR3 DNA sequence from the *CDKN1A* promoter had a deleted or mutated A-box sequence (Pol III promoter element). In vitro DNA-protein binding assays performed by the above method or colorimetric assay (Abcam, ab117139) both showed that the DNA with deleted or mutated A-box sequences exhibited significantly lower binding of MAF1, which indicates the specificity of MAF1 for the Pol III promoter element ([Figure 4A--C](#fig4){ref-type="fig"}). Moreover, consistent with ChIP data, MAF1 did not bind in vitro to the *ACTB* promoter that did not contain a SINE or sequences that would resemble the Pol III promoter element ([Figure 4A,B](#fig4){ref-type="fig"}). To the best of our knowledge, this is the first demonstration of direct binding of MAF1 to a specific DNA sequence.10.7554/eLife.06283.008Figure 4.In vitro binding and transcription assays demonstrate MAF1-regulated Pol III-mediated activation of Pol II-regulated genes.(**A**) Diagrams of Pol II promoters (*CDKN1A*, *ACTB*, *RPPH1*, and *GDF15*) with locations of exon 1, SINEs (red), and constructed DNA template (green arrow) for the in vitro MAF1 binding assay. (**B**) An in vitro DNA binding assay was performed as described in the 'Materials and methods'. In brief, DNA template, MAF1 protein (His-tagged), and Anti-6× His tag antibody were added to the binding reaction (Protein + Ab). A negative control was performed by substituting IgG antibody for Anti-6× His tag antibody (Protein + IgG) or with only the Anti-6× His tag antibody for the MAF1 protein (Ab only). DNA isolated from the immunoprecipitated protein--DNA complex was subjected to qPCR. Deletion of a SINE in the *CDKN1A* template as well as deletion or mutation of the Pol III A-box element in the *CDKN1A* and *GDF15* template depleted MAF1 binding. Binding of MAF1 to *RPPH1* or *ACTB* promoters was not detected. Data shown are the mean ± SD, *n* ≥ 3, \*\*p \< 0.01, \*\*\*p \< 0.001 (*t*-test). (**C**) An in vitro DNA--protein binding assay was performed using a colorimetric assay kit (ab117139). The assayed DNA template 'p21' (DNA template with a Pol III A-box element obtained from *CDKN1A*) was labeled with biotin (a probe). Purified MAF1 protein (His tag) (80R-1955, Fitzgerald) was used for the binding assay. Different competitors (described below) were added to the mixture to demonstrate the specificity of binding of MAF1 at the Pol III promoter element. Competitors: 'self' indicates the same DNA template without the biotin label, 'GDF' indicates the non-labeled DNA template that contained the Pol III promoter element obtained from the *GDF15* promoter, and 'Mut' indicates the Pol III A-box element was mutated in the DNA template. A blank control was performed without the addition of protein, and the degree of enrichment was calculated by subtracting the value of the blank control. MAF1 directly bound to the Pol III promoter element, but the mutant form did not. Data shown are the mean ± SD, *n* = 3, \*\*\*p \< 0.001 (*t*-test). (**D**) In vitro transcription assays were performed on *CDKN1A* and *TAF5* using the HeLaScribe^R^ Nuclear Extract in vitro Transcription System (Promega), as indicated in the 'Materials and methods'. Inhibition of Pol II transcription was performed by addition of α-amantin during in vitro transcription of *CDKN1A* and *TAF5*. The MAF1 protein was pre-incubated with template DNA before addition of nuclear extract to enable binding of MAF1 to the template DNA. (**E**) Different antibodies, as indicated, were pre-incubated with nuclear extract before adding template DNA to perform in vitro transcription to deplete the target protein of interest. For the control, no antibody was added prior to in vitro transcription. In vitro transcription performed on Pol III-transcribed *RPPH1* and Pol II-transcribed *TAF5* served as controls. In vitro transcription performed on *CDKN1A* and *GDF15* revealed that removal of MAF1 promoted transcription, whereas A-box-deleted *GDF15*, denoted as 'GDF15 (Del)', did not. The degree of enrichment of all performed in vitro transcription was calculated relative to the ratio of signals obtained from the input RNA after subtraction of the negative control (no biotin labeling). All data shown represent the mean ± s.e.m., *n* ≥ 3, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 (*t*-test).**DOI:** [http://dx.doi.org/10.7554/eLife.06283.008](10.7554/eLife.06283.008)

In vitro transcription using HeLa cell nuclear extract demonstrated that transcription of Pol II genes was reciprocally regulated by MAF1 and Pol III {#s2-5}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Although the several types of evidence discussed above strongly support the regulation of *CDKN1A* by recruitment of Pol III to the promoter, the effect observed in vivo nevertheless could be due to some other indirect effect. To directly demonstrate the enhancement of Pol II transcription by removing MAF1 and recruiting Pol III, we carried out in vitro transcription using commercial HeLa cell nuclear extract. Constructed DNA templates of the genes analyzed are described in the 'Materials and methods'. The in vitro, newly transcribed RNA was labeled with biotin, and the products were affinity purified. The nature of the affinity-purified nascent RNA was then analyzed by qRT-PCR. Negative control without biotin labeling was used. First, we showed that the in vitro transcription was indeed mediated by Pol II by inhibition of transcription either by α-amanitin treatment ([Figure 4D](#fig4){ref-type="fig"}) or by depletion of Pol II in the extract using anti-Pol II antibody ([Figure 4E](#fig4){ref-type="fig"}). When purified MAF1 protein was pre-incubated with DNA template prior to the addition of nuclear extract, *CDKN1A* transcription was repressed with respect to the control ([Figure 4D](#fig4){ref-type="fig"}). This result is consistent with in vivo expression analysis and the in vitro binding assay. Together these results suggest that MAF1 protein serves as repressor of *CDKN1A* transcription. As a control, pre-incubation with MAF1 protein did not affect *TAF5* transcription ([Figure 4D](#fig4){ref-type="fig"}) because MAF1 did not bind to this DNA template in vivo ([Figure 3I](#fig3){ref-type="fig"}).

When nuclear extract was pre-incubated with an anti-MAF1 antibody to deplete MAF1 during in vitro transcription, *CDKN1A* transcription was significantly upregulated compared with that of the control, which was pre-incubated with IgG or no antibody ([Figure 4E](#fig4){ref-type="fig"}). Simultaneous depletion of Pol III and MAF1 by pre-incubation nuclear extract with Pol III and MAF1 antibodies abolished the enhancement of transcription after depletion of MAF1 alone ([Figure 4E](#fig4){ref-type="fig"}). Specificity of the Pol III antibody was demonstrated by the inhibitory effect of anti-Pol III antibody on in vitro transcription of the Pol III-transcribed *RPPH1* promoter in a pSUPER plasmid. Addition of the anti-MAF1 antibody did not induce *RPPH1* transcription ([Figure 4E](#fig4){ref-type="fig"}) because binding of MAF1 was not detected in this gene by the in vitro MAF1 binding assay ([Figure 4B](#fig4){ref-type="fig"}).

These experiments recapitulated the in vivo transcription regulation of *CDKN1A* by MAF1 and Pol III. Taken together with the in vivo and in vitro nuclear run-on expression analyses, these results unambiguously demonstrate that MAF1 can serve as a repressor of the *CDKN1A* promoter, and that recruiting Pol III after MAF1 depletion is crucial for the activation of *CDKN1A* transcription.

*MAF1* knockdown promoted recruitment of positive regulatory factors and induced histone modifications associated with gene activation {#s2-6}
--------------------------------------------------------------------------------------------------------------------------------------

The data above indicate that binding of Pol III to the *CDKN1A* promoter after *MAF1* knockdown is crucial for enhanced transcription. This indicates that Pol III may help recruit the regulatory factors necessary for efficient Pol II transcription. To test this hypothesis, we carried out ChIP analysis to examine the Pol III-dependent recruitment of transcription activators after MAF1 removal. ChIP analysis showed that *MAF1* knockdown resulted in significantly enhanced levels of active histone modifications, including H3K4me3, H3K9Ace, and H3K27Ace, in the 5′ regions of *CDKN1A* ([Figure 5A,B](#fig5){ref-type="fig"}). The enhanced active histone marks after *MAF1* knockdown were abolished under simultaneous knockdown of Pol III and *MAF1* ([Figure 5B](#fig5){ref-type="fig"}). The histone repression marker, H3K27me3, was detected at the 5′ regions and decreased after *MAF1* knockdown, but the level was restored under simultaneous knockdown of Pol III and *MAF1* ([Figure 5B](#fig5){ref-type="fig"}).10.7554/eLife.06283.009Figure 5.*MAF1* knockdown induces Pol II initiation, active histone marks (H3K4me3, H3K9Ace, and H3K27Ace), and binding of CFP1, p300, PCAF, TBP, and POLR2E at the *CDKN1A* promoter.(**A**) Diagram of the *CDKN1A* promoter, including locations of exon 1 (Ex1), SINEs (AluSx and MIR3), and ChIP qPCR amplicons (p21-L, p1, p2, and p3). (**B**) Knockdown coupled with ChIP assays with antibodies for H3K27me3, H3K4me3, H3K27Ace, and H3K9Ace were performed in MCF-7 cells subjected to siRNA knockdown for 72 hr. DNA isolated from immunoprecipitated chromatin was subjected to qPCR and calculated as described in the 'Materials and methods'. Knockdown *MAF1* (KD MAF1) enhanced active histone marks H3K4me3, H3K27Ace, and H3K9Ace, whereas simultaneous knockdown of Pol III and *MAF1* (KD M/Pol III) abolished the enhanced histone marks. ChIP with anti-CFP1 (IP: CFP1) (**C**), anti-p300 (IP: p300) (**D**), anti-PCAF (IP: PCAF), (**E**) anti-TBP (IP: TBP) (**F**), and anti-POLR2E (IP: POLR2E) (**G**) antibodies were performed as described in (**B**). Knockdown *MAF1* (KD MAF1) enhanced binding of CFP1, p300, PCAF, TBP, and POLR2E, whereas simultaneous knockdown of Pol III and *MAF1* (KD M/Pol III) abolished the enhanced binding. All data shown are the mean ± s.e.m., *n* ≥ 3, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 (*t*-test).**DOI:** [http://dx.doi.org/10.7554/eLife.06283.009](10.7554/eLife.06283.009)10.7554/eLife.06283.010Figure 5---figure supplement 1.Enhanced gene expression by *MAF1* knockdown is abolished by simultaneous knockdown of *MAF1* with *TBP* or *CFP1*.(**A**) Quantitative RT-PCR of genes in MCF-7 cells subjected to siRNA knockdown of *MAF1*, *CFP1*, or simultaneous knockdown of both for 72 hr. *CDKN1A* expression was upregulated after *MAF1* knockdown, and the upregulation was abolished by simultaneous knockdown of *MAF1* and *CFP1*. (**B**) Quantitative RT-PCR of genes in MCF-7 cells subjected to siRNA knockdown of *MAF1*, *TBP*, or simultaneously knockdown of knockdown of *MAF1* and *TBP* for 72 hr. Expression of *CDKN1A* and *TBP* was upregulated after *MAF1* knockdown, and the upregulation was abolished by simultaneous knockdown of *MAF1* and *TBP*. Relative expression normalized to 18S is displayed. All data shown represent the mean ± SD, *n* ≥ 3, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 (*t*-test).**DOI:** [http://dx.doi.org/10.7554/eLife.06283.010](10.7554/eLife.06283.010)

Because H3K4 methylation is catalyzed by the SET1/MLL family of histone methyltransferases in humans ([@bib32]), we performed knockdown assays to investigate which methyltransferase is responsible for H3K4me3 modification after *MAF1* knockdown. Previously, CFP1 (SET1C-specific subunit) and p300 were shown to act cooperatively to regulate H3K4me3 modification and *CDKN1A* transcription ([@bib33]). Indeed, the *MAF1* knockdown-induced transcription of *CDKN1A* was downregulated after *CFP1* (CXXC1) knockdown ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}).

p300 and PCAF have been shown to regulate K27 and K9 acetylation, respectively, of the *CDKN1A* promoter ([@bib23]). Thus, we next analyzed whether CFP1, p300, and PCAF could bind to the *CDKN1A* promoter after *MAF1* knockdown. As expected, the removal of MAF1 by knockdown induced binding of CFP1, p300, and PCAF to the *CDKN1A* promoter ([Figure 5C--E](#fig5){ref-type="fig"}). Furthermore, simultaneous knockdown of *MAF1* and Pol III abolished the induced binding of these factors along with active histone marks, which indicates that Pol III is required to recruit these factors to the *CDKN1A* promoter for histone modifications ([Figure 5C--E](#fig5){ref-type="fig"}).

Because TBP is an important factor required in both Pol II (part of TFIIB) and Pol III (part of TFIIIB) transcription ([@bib39]), we next determined whether binding of TBP was enhanced after *MAF1* knockdown. Indeed, enhanced binding of TBP was observed at the *CDKN1A* promoter after *MAF1* knockdown, and the binding was abolished when there was simultaneous knockdown of Pol III and *MAF1* ([Figure 5F](#fig5){ref-type="fig"}). Simultaneous knockdown of *MAF1* and *TBP* also abolished the enhanced expression of *CDKN1A* by knockdown of only *MAF1* ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}), which indicates that TBP is important for *CDKN1A* transcription activation. We also observed enhanced binding of a common subunit of all three RNA polymerases, that is, POLR2E (RPB5), after *MAF1* knockdown, and this enhanced binding was also abolished when there was simultaneous knockdown of Pol III and *MAF1* ([Figure 5G](#fig5){ref-type="fig"}), indicating interplay between Pol II and Pol III polymerases.

Pol III is required for chromatin looping at the *CDKN1A* promoter after *MAF1* knockdown {#s2-7}
-----------------------------------------------------------------------------------------

Because binding of Pol III and Pol II was detected at the 5′ flanking regions of both long and short *CDKN1A* forms in the UCSC Genome Database after *MAF1* knockdown, we performed 3C analysis to investigate whether chromatin looping occurs between these two regions. Chromatin looping was detected between the regions after *MAF1* knockdown, but not in adjacent regions ([Figure 6A,B](#fig6){ref-type="fig"}). Moreover, simultaneous knockdown of *MAF1* with either Pol III or *BRF1* (a subunit of TFIIIB) disrupted the looping formation ([Figure 6C](#fig6){ref-type="fig"}). These results demonstrate that Pol III is required for induced chromatin looping after *MAF1* knockdown.10.7554/eLife.06283.011Figure 6.Pol III is required for chromatin looping at the *CDKN1A* promoter after *MAF1* knockdown.(**A**) Schematic diagram of *CDKN1A* with the orientation of 3C primers (arrows: 5r, 4r, 3r, 2r, and 2f) and location of exon 1 (long form: L-Ex1; short form: Ex1). (**B**) MCF-7 cells were subjected to siRNA knockdown of *MAF1* (KD MAF1) for 72 hr. 3C assay was performed as indicated in the 'Materials and methods', and DNA was subjected to PCR. Chromatin looping was detected after *MAF1* knockdown from 2r to 2f (top panel) and are shown by a representative gel (bottom panel). (**C**) The induced chromatin looping after *MAF1* knockdown was diminished when either Pol III (KD M/Pol III) or *BRF1* (KD M/BRF1) underwent simultaneous knockdown with *MAF1* (top panel) and are shown by a representative gel (bottom panel). All data shown represent the mean ± s.e.m., *n* ≥ 3, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 (*t*-test).**DOI:** [http://dx.doi.org/10.7554/eLife.06283.011](10.7554/eLife.06283.011)

Pol III is required for transcriptional activation and chromatin looping of *GDF15* after *MAF1* knockdown {#s2-8}
----------------------------------------------------------------------------------------------------------

The above results demonstrate that *MAF1* knockdown can activate *CDKN1A* expression by recruiting Pol III and Pol II along with histone-modifying factors. To demonstrate that this type of mechanism also regulates expression of other Pol II genes, we performed expression analysis of *GDF15*, which is another cell proliferation-related gene that is upregulated after *MAF1* knockdown as found by microarray analysis. As expected, qRT-PCR analysis showed that *GDF15* expression was strongly upregulated after *MAF1* knockdown, and simultaneous knockdown of *MAF1* with Pol III diminished the induced expression ([Figure 1D](#fig1){ref-type="fig"}). ChIP analysis also indicated binding of MAF1 at the 5′ flanking region of *GDF15* ([Figure 7A,B](#fig7){ref-type="fig"}).10.7554/eLife.06283.012Figure 7.Pol III is required for chromatin looping at the *GDF15* promoter after *MAF1* knockdown.(**A**) Schematic diagram of *GDF15* with ChIP--qPCR amplicons (AluSx, 3C, MIR, p1, p2, and p3), the orientation of 3C primers (arrows: 3C-3r, 3C-2r, and 3C-1f), and locations of exons (Ex1 and Ex2). (**B**) ChIP with anti-MAF1 antibody (IP: MAF1) was performed in MCF-7 cells subjected to siRNA knockdown of *MAF1* (KD MAF1) or simultaneous knockdown of *MAF1* and Pol III (KD M/Pol III) for 72 hr. Binding of MAF1 was detected at the *GDF15* promoter, which diminished after *MAF1* knockdown. (**C**) A 3C assay was performed as indicated in the 'Materials and methods', and DNA was subjected to PCR. Chromatin looping was detected after *MAF1* knockdown from 3C-3r to 3C-1f (top panel) and is shown by a representative gel (bottom panel). (**D**) The induced chromatin looping after *MAF1* knockdown (KD MAF1) was diminished when *MAF1* underwent simultaneous knockdown with either Pol III (KD M/Pol III) or *BRF1* (KD M/BRF1) (top panel) and is shown by a representative gel (bottom panel). (**E**) ChIP with anti-Pol III antibody (IP: Pol III) or anti-Pol II antibody (IP: Pol II) was performed in MCF-7 cells subjected to siRNA knockdown. Enhanced binding of Pol III was detected at the *GDF15* promoter after *MAF1* knockdown, which was abolished when there was simultaneous knockdown of Pol III and *MAF1* (KD M/Pol III). (**F**) *MAF1* knockdown indicates enhanced binding of serine 5-phosphorylated Pol II, which was abolished when there was simultaneous knockdown of Pol III and *MAF1*. All data shown represent the mean ± s.e.m., *n* ≥ 3, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 (*t*-test).**DOI:** [http://dx.doi.org/10.7554/eLife.06283.012](10.7554/eLife.06283.012)

We also employed an in vitro transcription assay using HeLa cell nuclear extract to demonstrate the importance of the Pol III promoter element in regulation of *GDF15* transcription after *MAF1* knockdown. When nuclear extract was pre-incubated with anti-MAF1 antibody to deplete MAF1 during in vitro transcription, *GDF15* transcription was significantly upregulated compared with the control with pre-incubation with IgG or no antibody ([Figure 4E](#fig4){ref-type="fig"}). We also noticed an MIR repeat element in the 5′ flanking region of *GDF15*. As in the case of *CDKN1A*, deletion of the Pol III A-box element associated with this repeat also abolished the enhancement of *GDF15* in vitro transcription when anti-MAF1 antibody was added to the extract ([Figure 4E](#fig4){ref-type="fig"}), indicating that this element mediated MAF1 binding. Indeed, the in vitro binding assay using purified MAF1 protein indicated that MAF1 did not bind to this deletion mutant but did bind to the wild-type sequence ([Figure 4B](#fig4){ref-type="fig"}).

A 3C assay was performed to further investigate whether *MAF1* knockdown induces chromatin looping. The analysis indicated that there was chromatin looping between a promoter region and a region that is 12-kb upstream of the *GDF15* promoter after *MAF1* knockdown ([Figure 7C](#fig7){ref-type="fig"}). Furthermore, the looping was abolished under simultaneous knockdown of *MAF1* with either Pol III or *BRF1* ([Figure 7D](#fig7){ref-type="fig"}). Similar to the *CDKN1A* results, induced binding of Pol III and Pol II to the *GDF15* promoter was observed after *MAF1* knockdown, whereas the binding was diminished after simultaneous knockdown of Pol III and *MAF1* ([Figure 7E,F](#fig7){ref-type="fig"}). These results show that transcription of *GDF15*, like *CDKN1A*, is upregulated after *MAF1* knockdown by recruiting Pol III, and Pol III is required for chromatin looping at the *GDF15* promoter.

Demonstration of MAF1- and Pol III-mediated transcription regulation using a reporter gene assay {#s2-9}
------------------------------------------------------------------------------------------------

To demonstrate the role of the Pol III promoter element in Pol III-mediated activation of the Pol II gene, we analyzed the effect of deletion of the Pol III promoter element using a reporter assay. The promoter regions of *CDKN1A*, *GDF15*, and *TAF5*, as indicated in the 'Materials and methods', were cloned into the reporter plasmid pGL3. Promoter-driven luciferase activities of *CDKN1A* and *GDF15* were upregulated, whereas *TAF5* promoter-driven expression was not affected after *MAF1* knockdown ([Figure 8A](#fig8){ref-type="fig"}). Simultaneous knockdown of both Pol III and *MAF1* abolished the upregulation caused by knockdown of *MAF1* alone ([Figure 8A](#fig8){ref-type="fig"}). These results thus recapitulated the results of in vivo endogenous gene analysis.10.7554/eLife.06283.013Figure 8.Demonstration of MAF1- and Pol III-mediated transcription regulation using a reporter gene assay.(**A**) Promoter regions of Pol II genes were constructed and cloned into pGL3-basic reporter plasmids, as indicated in the 'Materials and methods'. Luciferase reporter assays were performed in MCF-7 cells subjected to siRNA knockdown of *MAF1* or simultaneous knockdown of Pol III and *MAF1*. Results are normalized with β-galactosidase and presented relative to knockdown control cells transfected with pGL3-basic. (**B**) The consensus sequence of the A-box (−447 to −437) in the *GDF15* promoter (−889 to +110) was either deleted or mutated. Reporter assays were performed in MCF-7 cells subjected to siRNA knockdown of *MAF1* (KD MAF1). All data shown represent the mean ± s.e.m., *n* ≥ 3, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 (*t*-test).**DOI:** [http://dx.doi.org/10.7554/eLife.06283.013](10.7554/eLife.06283.013)

Because the majority of SINEs are transcribed by the type II internal Pol III promoter that contains an A-box and B-box ([@bib25]), our model indicates that mutation of the Pol III promoter element in the promoter-associated SINE should abolish the enhancement of reporter expression after *MAF1* knockdown. To test this possibility, we chose the *GDF15* promoter for analysis because it was shown ([@bib16]) that deletion of the −465 to −429 sequence, which contains the Pol III promoter element, did not affect promoter activity. We mutated the A-box (−447 to −437) in the *GDF15* promoter (−889 to +110) in the reporter and examined the effect of mutation on reporter expression. Under regular cell culture conditions, no significant change in *GDF15* promoter activity was observed in our results when the A-box was mutated or deleted, in consistent with the results of [@bib16]. However, deletion of A-box in the *GDF15* promoter diminished the upregulation of the reporter after *MAF1* knockdown ([Figure 8B](#fig8){ref-type="fig"}). These results further demonstrate that MAF1 represses *CDKN1A* and *GDF15* promoter activity by binding to the Pol III promoter element. Moreover, recruitment of Pol III after MAF1 depletion is crucial for transcription activation of these genes.

Discussion {#s3}
==========

In this research, we showed that MAF1 bound to promoter-associated SINEs associated with type II Pol III promoters and that depletion of MAF1 enhanced transcription activity and chromatin looping by the recruitment of Pol III along with active Pol II and factors associated with these promoters. Both in vivo gene expression and R-looping analysis as well as in vitro transcription using the HeLa nuclear extract and in vitro binding using purified MAF1 protein revealed that MAF1 represses *CDKN1A* and *GDF15* promoter activity by binding to the SINE repeats within their promoters. This result strongly indicates a novel transcription regulatory mechanism whereby MAF1 also acts as a specific repressor of some Pol II genes by binding to promoter-associated SINEs. Binding specificity was demonstrated by an in vitro DNA binding assay with purified MAF1 to wild-type *CDKN1A* and *GDF15* promoters and the lack of binding to promoters with mutations in the SINE. To the best of our knowledge, this is the first time that MAF1 has been shown to bind to specific DNA sequences.

We also demonstrated that recruiting Pol III to SINEs in the 5′ flanking region is required to promote Pol II gene transcription, epigenetic modifications, and chromatin looping after *MAF1* knockdown. Recruitment of Pol III, positive regulatory factors, and common transcription factors (TBP and POLR2E) of Pol II and Pol III demonstrate a novel mechanism of activating Pol II genes through Pol III-mediated activation mechanism. Gene expression induced by chromatin remodeling through SINEs has also been described in neuronal genes that undergo acetylation of distal promoter SINEs by p300 to translocate genes to transcription factories ([@bib9]). In our result, *MAF1* knockdown promoted recruitment of p300, which has been shown to promote acetylation of histone K27 and active transcription by Pol II. However, how extensively this mechanism regulates genes is currently unknown.

Histone H3K4me has been suggested to serve as a hallmark of enhancer ([@bib15]). Examination of ENCODE database revealed that this epigenetic mark was presented in both 5′ flanking regions of *CDKN1A*. Indeed the identified p53-binding site located between 1.4 kb and 2.3 kb upstream of *CDKN1A* has been identified as the enhancer region ([@bib24]; [@bib22]). However, the SINE with the MAF1-binding site located at 2.65 kb upstream of short promoter exerted no enhancer activity in the luciferase assay prior to or after *MAF1* knockdown (data not shown). The chromatin looping we observed for *CDKN1A* and *GDF15* after *MAF1* knockdown may be mediated through the proximity and interaction between the sets of transcriptional factors recruited in the two 5′ flanking regions after chromatin remodeling as proposed by [@bib9].

Because the background expression of Pol II genes slightly decreased when Pol III was knockdown, Pol III may be able to regulate the expression of some minor alleles without MAF1 being bound to the promoter. However, it is difficult to unequivocally validate this possibility without specific technology that can efficiently separate different alleles in cells.

Human genome analysis indicated that 71% of genes contained SINEs in their promoter regions. Microarray analysis showed that 124 genes were upregulated after *MAF1* knockdown. Of these, 76% contained SINEs within the promoter region, which indicates the regulation potential of these genes by MAF1 and Pol III. However, microarray analysis of steady-state mRNA level alone is not sufficient to show whether these genes are directly regulated by MAF1 at the transcriptional level or as the result of downstream secondary effects. Further analysis using in vitro transcription, reporter gene analysis, and nuclear run-on would be required to unambiguously establish how general Pol II genes are regulated by MAF1 and Pol III. In vitro transcription using HeLa cell extracts with depletion or addition of specific transcription regulators could provide very strong support of the involvement of specific factors in transcription regulation.

Close proximity of Pol III genes to Pol II genes has been observed genome-wide ([@bib26]). Active Pol III-transcribed genes and non-coding RNAs often associate with Pol II transcription start sites. Pol II and its associated epigenetic marks are also present at active Pol III-transcribed genes ([@bib4]; [@bib29]; [@bib7]). This shows that there is common epigenetic regulation between these two types of transcription units, and the polymerases may work with one another to regulate gene expression. Indeed, cross-talk between Pol III and Pol II transcription factors, such as TFIIS in Pol III transcription, has also been reported in yeast and mice ([@bib12]; [@bib8]). The core Pol III transcription factor TFIIIC can also directly regulate transcription from a Pol II promoter ([@bib19]). Binding of TFIIIC to SINE promoters has been shown to mediate the relocation and transcription of neuronal genes ([@bib9]). *RPPH1*, to which BRF2, Pol III, GTF2B, and Pol II bind, can be transcribed by either Pol II or Pol III ([@bib17]). Our results indicate that Pol III and Pol II association may have functional relevance for genome functional organization, because simultaneous knockdown of both Pol III and *MAF1* diminished the induced active transcription caused by knockdown of only *MAF1*. Furthermore, enhanced binding of TBP to TFIIIB and TFIIB can lead to formation of Pol III and Pol II complexes to initiate transcription ([@bib39]). We propose that this type of SINE-associated-Pol II promoter architecture may introduce an additional layer of control in gene expression.

Recently, MAF1 was shown to be a negative regulator of transcription of all three polymerases, Pol I, Pol II, and Pol III, through mediating *TBP* expression ([@bib18]). Johnson et al. showed that MAF1 binds to the Elk-1-binding site of the *TBP* promoter to prevent the binding of Elk-1. Indeed, there is a SINE with an A-box (−10 to +1) and B-box (−105 to −95) that encompass the Elk-1-binding site of the *TBP* promoter. In our analysis, *MAF1* knockdown only slightly increased *TBP* expression (1.6-fold) compared with the results reported by Johnson et al. (twofolds). This may be due to the already high expression of *TBP* in cell lines, and we did not detect binding of MAF1 to this active promoter.

Based on our results, we propose the following mechanism of control of Pol II gene transcription by MAF1 and Pol III: Before removal of MAF1 from SINEs, Pol II is in a transcriptionally engaged but paused state, where TBP/TFIIB is pre-assembled and remains at the promoter ([@bib14]; [@bib20]; [@bib36]). Removal of *MAF1* by knockdown then leads to recruitment of TFIIIB through enhanced binding of TBP; the shared surface of TBP then directs both Pol II and Pol III binding through association with TFIIB and TFIIIB, respectively. Further recruitment of active regulatory factors would then induce transcription by Pol II and Pol III. This model is consistent with those proposed by previous studies, which were based on a component of TBP-associated complexes, p300, interacting with SET1C-coupled histone modifications to activate *CDKN1A* transcription ([@bib2]; [@bib33]). Moreover, our model is also supported by a previous study on the relocation of inducible neuronal genes to transcription factors that involve acetylation of distal promoter SINEs by p300 ([@bib9]).

Materials and methods {#s4}
=====================

Cell culture {#s4-1}
------------

MCF-7, MCF-10A, and MDA-MB-231 cell lines were originally obtained from ATCC (Manassas, VA), and cultured in RPMI, HuMEC and DMEM medium (Invitrogen; Waltham, MA), respectively. HCT-116^p53+/+^ (wild-type) and HCT116^p53−/−^ (p53-null) cell lines were originated from Bert Vogelstein (John Hopkins University) and cultured in McCoy\'s 5A medium ([@bib6]). Each medium was supplemented with 10% of fetal bovine serum and incubated in a humidified 37°C incubator with 5% CO~2~.

RNAi knockdown assay {#s4-2}
--------------------

Knockdown assay was performed using siRNA obtained from MISSION RNA (Sigma-Aldrich; St. Louis, MO). Inhibition of expression of *MAF1* (\[\#1\] SASI_Hs01_00135954, \[\#2\] SASI_Hs01_00135956 and \[\#3\] SASI_Hs01_00135958), Pol III (POLR3A) (\[\#1\] SASI_Hs01_00046568, \[\#2\] SASI_Hs01_00046571 and \[\#3\] SASI_Hs01_00046572), *BRF1* (SASI_Hs01_00131187), *CFP1* (SASI_Hs02_00322879), and *TBP* (SASI_Hs01_00122768) was achieved by transfection with Lipofectamine RNAiMax (Invitrogen) according to the manufacturer\'s protocol for 72 hr. MISSION siRNA Universal Negative Control (Sigma) was used as knockdown control. Cells were transfected in serum-free medium. After 8 hr, the siRNA containing medium was replaced with complete medium.

Immunoblotting {#s4-3}
--------------

Cells were lysed at 4°C in RIPA lysis buffer (50 mm Tris-HCl, pH 7.2, 150 mm NaCl, 5 mm EDTA, 1% \[wt/vol\] NP-40, 1% \[wt/vol\] SDS and protease and phosphatase inhibitor mixtures \[Roche Applied Science; Penzberg, Germany\]). The lysates were cleared by centrifugation (15,000×*g* for 15 min), resolved on a 10% SDS-polyacrylamide gel, and transferred onto a nitrocellulose membrane. The antibody dilutions used were rabbit anti-POLR3A (1:1000; ab96328, Abcam; Cambridge, England), rabbit anti-MAF1 (1:1000; GTX106776, Acris; Herford, Germany), rabbit anti-CDKN1A (1:1000; ab18209, Abcam), and mouse anti-tubulin (1:10,000; ab7291, Abcam).

RNA extraction {#s4-4}
--------------

Cells were grown to 85% confluence in 6 cm tissue culture dish. Each 6 cm dish was washed with 1× phosphate buffered saline (PBS) for three times. Total RNA was extracted using TRIreagent (Invitrogen) protocol. The integrity of the RNA extract was checked by 1.2% (wt/vol) agarose gel electrophoresis and the concentration of RNA was estimated by ultraviolet spectrophotometry.

Microarray {#s4-5}
----------

Affymetrix microarray was performed using Human U133 plus 2.0 (Affymetrix; Santa Clara, CA). Details of the methods for RNA quality, sample labeling, hybridization, and expression analysis were according to the manual of Affymetrix Microarray Kit. All Affymetrix data are MIAME compliant and that the raw data have been deposited in a MIAME compliant database, GEO. The microarray data were deposited at the NCBI GEO website (GEO accession number GSE42239).

Quantitative RT-PCR {#s4-6}
-------------------

Reverse transcription was performed by using superScript III RNase H- Reverse Transcriptase (Invitrogen) and random hexamer according to the manufacturer\'s protocol. Quantitative PCR was performed using KAPA SYBR FAST (KK4603, KAPA Biosystems; Wilmington, MA) on ABI StepOnePlus Real-Time PCR System (Invitrogen). All reactions were performed in triplicate with KAPA SYBR FAST plus 10 μM of both the forward and reverse primer according to the manufacturer\'s recommended thermo cycling conditions, and then subjected to melting curve analysis. The calculated quantity of the target gene for each sample was divided by the average sample quantity of the housekeeping genes, glyceraldehydes-3-phosphate dehydrogenase (*GAPDH*) or 18S to obtain the relative gene expression.

Flow cytometry analysis {#s4-7}
-----------------------

MCF-7 knockdown cells were collected by trypsinization and washed twice with ice-cold PBS. The cells were resuspended in 0.3 ml of PBS and fixed by slowly adding 3 ml of 70% cold ethanol. Cells were fixed at −20°C for 1 hr. The fixed cells were washed with ice-cold PBS and rehydrated for 15 min. After centrifuging at 200×*g* for 5 min, cells were resuspended in 0.1 mg/ml of propidium iodide and 0.6% of Triton X-100 in 500 μl of PBS. Then add 500 μl of 2 mg/ml of RNase A and incubate in the dark for 45 min. Data were collected using a FACScan flow cytometry system (BD; Franklin lakes, NJ).

Nuclear run-on assay {#s4-8}
--------------------

Nuclear run-on reactions were performed by supplying biotin-16-UTP to nuclei, and labeled transcripts were bound to streptavidin-coated magnetic beads as described by [@bib27] with minor modifications. Nuclei were prepared from MCF-7 cells by resuspension in Nonidet P-40 lysis buffer (10 mM HEPES, pH 7.3, 10 mM NaCl, 3 mM MgCl~2~, 150 mM sucrose, and 0.5% Nonidet P-40). Nuclei were isolated, and the pellets were resuspended in 1 ml of glycerol buffer (50 mM Tris-Cl, pH 8.3, 40% glycerol, 5 mM MgCl~2~, and 0.1 mM EDTA). 1 ml of transcription buffer (20 mM Tris-Cl, pH 8.0, 200 mM KCl, 5 mM MgCl~2~, 4 mM dithiothreitol, 4 mM each of ATP, GTP, and CTP, 200 mM sucrose, and 20% glycerol) was added in the nuclei along with 10 μl of biotin-16-UTP or UTP for run-on reaction or negative control, respectively (Roche). After incubation at 29°C for 30 min, the reaction was terminated by the addition of 12 μl of 250 mM CaCl~2~, and 12 μl of RNase-free DNase I and incubated at 29°C for 10 min. To purify RNA, a TRIreagent extraction, phenol-chloroform extraction, and isopropanol (Sigma) precipitation were then performed. A small aliquot (5 μl from a total of 50 μl) was saved as input control. Dynabeads M-280 streptavidin (Invitrogen) were mixed with an equal volume of the isolated RNA samples for 20 min at 42°C for 20 min and 2 hr at room temperature. After washing with 15% formamide and 2× SSC, the beads were resuspended in 45 μl of nuclease-free water. Reverse transcription was performed by using superScript III RNase H---Reverse Transcriptase (Invitrogen). Total cDNA was then synthesized by means of random hexamer primed reverse transcription of captured molecules. The gel pictures were quantified with ImageJ (provided by NIH: <http://imagej.nih.gov/ij/>). The purified run-on products where normalized with internal control (*GAPDH*) to obtain the relative transcription levels for each gene.

Detection of R loops using non-denaturing bisulfite treatment {#s4-9}
-------------------------------------------------------------

Knockdown assay was performed using siRNA obtained from MISSION RNA (Sigma). Inhibition of expression of Pol III (SASI_Hs01_00046568) and *MAF1* (SASI_Hs01_00135954) was achieved by transfection with Lipofectamine RNAiMax (Invitrogen) according to the manufacturer\'s protocol for 72 hr. DNA purification and single-stranded R loop foot-printing were carried out as previously described with slight modifications ([@bib38]). 500 ng of purified genomic DNA was bisulfite converted by adding CT Conversion Reagent from the EZ DNA Methylation-Gold Kit (Zymo Research; Irvine, CA) at 37°C for 16 hr in the dark. PCR amplified region for cloning is shown in [Figure 2A,F](#fig2){ref-type="fig"} as foot-printing region. The PCR product was gel eluted and ligated to sequencing vector yT&A (Sigma). Approximately, 20 individual clones were sequenced for all PCR products, and the sequencing data were analyzed and aligned to *CDKN1A* or *ACTB* genomic sequence. The sequence of the beginning and end of each clone is trimmed due to low quality of sequencing. A background conversion (approximately 5% of cytosine) may be seen possibly due to DNA breathing during the prolonged incubation at 37°C in our data and others ([@bib38]). Approximately, 1--2 clones showed both cytosine to thymine and guanine to adenine conversions, which is known as 'mosaic molecules' ([@bib38]).

ChIP and qPCR {#s4-10}
-------------

ChIP assay was performed according to the manufacturer\'s protocol (Upstate Biotechnology, Inc.; Lake Placid, NY) with slight modifications. Human MCF-7 cells were fixed with 1% of formaldehyde at room temperature for 10 min. The cells were lysed and the chromatin was sonicated to 200--500 bp fragments by Bioruptor sonicator (cycle condition of 25 s on and 25 s off in a total of 25 min at highest output). Chromatin was immunoprecipitated by using Pol III (ab96328, Abcam), Pol II (ab5131, Abcam), MAF1 (GTX106776, Acris), H3K4me3 (04--745, Millipore; Billerica, MA), H3K27me3 (ABE44, Millipore), TBP (ab28175, Abcam), H3K9Ace (06--942, Millipore), H3K27Ace (07--360, Millipore), CFP1 (ABE211, Millipore), p300 (05--257, Millipore), POLR2E (ab180151, Abcam) BRF1 (ab74221, Abcam)or IgG (ab46540, Abcam) antibody, with 10 μg/ml of BSA and 50 μl of Dynabeads Protein A and G (Invitrogen) for overnight at 4°C. The beads were washed once with each washing buffer, including low salt immune complex wash buffer, high salt immune complex wash buffer, and LiCl immune complex wash buffer, and twice with 1× TE buffer. Precipitates were eluted with 1% of SDS and 100 mM of NaHCO~3~. Proteinase K was added to the samples, and rotated at 65°C for 2 hr followed by 95°C for 10 min and cooled down to room temperature. RNase A was added and samples were incubated at 37°C for 1 hr. After genomic DNA extraction, qPCR was performed. The degree of enrichment is calculated relative to the ratio of signals obtained in the input DNA fraction subtracting IgG-immunoprecipitated DNA.

3C assay {#s4-11}
--------

3C assay was performed according to ([@bib10]) with some modifications. MCF-7 cells were fixed in 2% formaldehyde for 10 min at room temperature and quench with 0.125 M glycine. After centrifugation for 15 min at 3500 rpm, the cells were suspended in lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.2% Nonidet P-40 and 1:500 Complete protease inhibitor cocktail; Roche) for 90 min on ice. Next, the nuclei were pelleted by centrifugation for 15 min at 2500 rpm, resuspended in 500 μl of 1× NEB buffer 4 plus 0.3% SDS and incubated at 37°C for 1 hr. After the addition of Triton-X to a final concentration of 1.8% to sequester the SDS, the mixture was incubated at 37°C for 1 hr, which was followed by the addition of 800 U of PstI and incubation at 37°C overnight to digest the chromatin. The reaction was terminated by adding SDS to a final volume of 1.6% and then the solution heated to 65°C for 20 min. Ligation of DNA in situ was carried out using 0.5--2.0 ng/μl of chromatin in 800 μl of ligation buffer (NEB; Ipswich, MA) plus 1% Triton-X and 30 Weiss Units of T4 ligase (NEB) for 4 hr at 16°C. After reversing of the crosslinks with proteinase K digestion at 65°C overnight, the DNA was purified by phenol-chloroform extraction and ethanol precipitation. The ligation products were detected by PCR using primers located near Pst1 cutting sites. The PCR products were purified from an agarose gel, cloned and sequenced.

In vitro DNA binding assay coupled with immunoprecipitation and qPCR {#s4-12}
--------------------------------------------------------------------

*CDKN1A* (with or without MIR3), *ACTB*, *GDF15* (including deleted or mutated A-box) and *RPPH1* template DNA was obtained by PCR followed by gel elution (Qiagen; Venlo, Netherlands) according to the manufacturer\'s protocol. The deletion of MIR3 was performed as described by PCR-mediated deletion and checked by sequencing ([@bib21]). The purified DNA was further used for in vitro DNA binding reactions as described previously with slight modifications ([@bib5]; [@bib34]). The in vitro protein-DNA binding assay coupled with immunoprecipitation was performed as following: 20 ng of DNA template, 400 ng of MAF1 protein (His tag) (80R-1955, Cantor Fitzgerald; New York, NY), 400 ng of Anti-6X His tag antibody (ab18184, Abcam), protease inhibitor (539134, Calbiochem; La Jolla, CA), and 200 ng of BSA was added into 50 μl of binding buffer (20 mM HEPES \[pH7.6\], 150 mM NaCl, 0.25 mM EDTA, 10% glycerol, 0.2% NP40, and 1 mM DTT). A negative control was performed by substituting IgG antibody for Anti-6× His tag antibody (Protein + IgG) or with only the Anti-6× His tag antibody for the MAF1 protein (Ab only). The mixture was rotated at 4°C for 10 min and on ice for 30 min. 10 μl of Dynabeads Protein G (Invitrogen) was added to the mixture and rotated at 4°C for 10 min and on ice for 30 min. The immunoprecipitated DNA-protein complexes were then washed twice with washing buffer (20 mM Tris \[pH 7.5\], 0.25 mM EDTA, 10% glycerol, and 0.2% NP40) and once with TE buffer by each rotating at 4°C for 5 min. Elution was performed with 1% of SDS and 0.1 M of NAHCO~3~. Input DNA was prepared as 1 ng of template DNA (5% of 20 ng). Proteinase K was added to the samples, and rotated at 65°C for 2 hr followed by 95°C for 10 min and cooled down to room temperature. DNA isolated from immunoprecipitated protein-DNA complex was subjected to qPCR. The degree of enrichment is calculated relative to the ratio of signals obtained in the input DNA fraction.

In vitro DNA-Protein binding colorimetric assay {#s4-13}
-----------------------------------------------

Biotin-labeled (labeled at 5′) and non-labeled *CDKN1A* (5′-AATCAACAACTTTGTATACTTAAGTTCAGTGGACCTCAATTTCCTCATCTGTGAAATAAA-3′) as well as mutated A-box template DNA (5′-AATCAACAACTTTGTATA CTTCCCATCCCAAAACCTCAATTTCCTCATCTGTGAAATAAA-3′) was obtained by oligo synthesis from Genomics (Houston, TX). The oligos were annealed and used for in vitro DNA-protein binding assay by the DNA-Protein Binding Assay Kit (Colorimetric) provided by Abcam (ab117139). The assay was performed according to manufacturer\'s protocol. In brief, 40 ng of biotin-labeled DNA template and 500 ng of MAF1 protein (His tag) (80R-1955, Fitzgerald) was used for the binding assay. For competition assay, 200 ng of competitor DNA was added to the mixture. Anti-6× His tag antibody (ab18184, Abcam) and Goat anti-Mouse IgG2b heavy chain (HRP) antibody (ab97250, Abcam) were prepared and added according to manufacturer\'s protocol. Blank control was performed without the addition of protein as specified by the kit and the degree of enrichment is calculated by subtracting with blank control.

Luciferase assay {#s4-14}
----------------

The upstream promoter regions of *CDKN1A* (−864 to +41 of NM_001220778 for short form and −1249 to +92 of NM_001220777 for long form), *GDF15* (−889 to +110), and *TAF5* (−998 to +157) genes were cloned into the pGL3-basic Reporter Vector (Promega; Fitchburg, WI). Knockdown assay was performed as mentioned above for 24 hr before MCF-7 cells were transfected with the plasmids using Lipofectamine LTX (Invitrogen), along with a plasmid expressing β-galactosidase for normalization. The plasmids were transfected for 48 hr, and the cells were lysed and luciferase assay was conducted using the Luciferase Assay System (Promega) using a fluorimetric plate reader.

In vitro Transcription System {#s4-15}
-----------------------------

In vitro transcription was performed by using HeLaScribe^R^ Nuclear Extract in vitro Transcription System (Promega Cat. \#E3110) according to the manufacturer\'s protocol with slight modifications. Template DNA was prepared by linearizing the constructed promoter region of *CDKN1A*, *GDF15*, and *TAF5* as used in Luciferase assay, as well as *RPPH1* promoter as used in in vitro MAF1 binding assay. In vitro transcription was performed by incubation with linear form of constructed promoter region with nuclear extract, transcription buffer, magnesium ion, GTP, CTP, ATP, biotin-16-UTP, RNase inhibitor, and 30 μg of yeast tRNA. Negative control was performed by incubation with non-biotin labeled NTPs. 0.2 μg of α-amanitin was added during in vitro transcription for inhibition of Pol II transcription. 3 μg of MAF1 protein (His tag) (80R-1955, Fitzgerald) used in in vitro MAF1 binding assay was pre-incubated with template DNA before adding nuclear extract to enable binding of MAF1 to the template DNA. Anti-Pol III (ab96328, Abcam), anti-Pol II (ab5131, Abcam), anti-MAF1 (GTX106776, Acris), or anti-IgG (ab46540, Abcam) antibody was pre-incubated with nuclear extract for 15 min to deplete the target protein of interest. After incubation at 30°C for 1 hr, the reaction was terminated by the addition of 175 μl of HeLa Extract Stop Solution (Promega Cat. \#E3110). A TRIreagent extraction, phenol-chloroform extraction, and isopropanol (Sigma) precipitation were then performed to purify RNA. A small aliquot (2 μl from a total of 22 μl) was saved as 'total nuclear RNA' for each condition. The biotinylated RNA was isolated using streptavidin-coated magnetic beads as described in Run-on assay. Reverse transcription was performed by using superScript III RNase H- Reverse Transcriptase (Invitrogen). Total cDNA was then synthesized by means of random hexamer primed reverse transcription of captured molecules.
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Major dataset {#s6-1}
-------------

The following dataset was generated:

Lee Y, Li Y, 2015,MAF1 Represses CDKN1A through a Pol III-Dependent Mechanism,<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42239>,Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSE42239).

Standard used to collect data: All Affymetrix data are MIAME compliant and that the raw data have been deposited in a MIAME compliant database, GEO. The microarray data were deposited at the NCBI GEO website (GEO accession number GSE42239).
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "MAF1-regulated-Pol III-mediated activation of *CDKN1A* through promoter looping" for consideration at *eLife*. Your article has been evaluated by James Manley (Senior editor) and four reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

The reviewers found the findings to be potentially exciting as they extend and expand thinking about how protein-coding genes are transcribed, in particular a novel role for RNA polymerase III in this process. Overall, this report presents some exciting new findings that are very timely in view of (i) extensive ChIPseq data in the literature demonstrating the localization of components of the Pol III transcription machinery adjacent to Pol II-transcribed genes and (ii) the widespread localization of SINE elements (of unknown function) in the human genome and near promoters. However, the reviewers found several issues that must be addressed in the revised manuscript before it could be recommended for publication:

1\) The possible role of p53. The two genes examined throughout the manuscript, *CDKN1A* and *GDF15*, are the two most potently transcribed p53 target genes (Allen et al., *eLife* 2014). However, the authors do not examine the effects that p53 may play in their system. It is entirely possible that most of the effects described upon *MAF1* knockdown are driven indirectly by activation of p53 downstream of a cellular stress response caused by deregulated RNAPIII function. The authors should check for p53 induction upon *MAF1* knockdown. Key experiments should be repeated in an isogenic system -/+ p53. This could be done with stable p53 knockdown MCF7 cells (Agami et al.) or HCT116 p53 -/+ cells (Vogelstein et al.).

2\) Promoter definition. The authors indicate that 'Examination of *CDKN1A* gene shows that there are two promoter regions (hereafter referred as long and short form)'. This description contrasts with many earlier reports that clearly show a major promoter for *CDKN1A* with minor alternative start sites. What exactly are the long and short forms? What NM genebank reference numbers do they correspond to? Where are they located relative to the well-characterized p53 enhancers? Importantly, the authors show equivalent Ser5-phospho-RNAPII binding to both promoters, but high H3K4me3 and TBP binding are found only at the downstream promoter encoding the 'short form', indicating that this promoter is the functional promoter. Confusingly, although the authors show equivalent binding of Ser5-phospho-RNAPII to both promoters, RBP5, a subunit common to all three polymerases is found preferentially at the downstream promoter. How much RNA is being produced from the 'long' and 'short' promoters? Some form of quantitative assay should be done to define the relative strength and RNA output of these two 'promoters'.

3\) Massive misinterpretation of 'chromatin looping' data. The authors repeatedly state throughout the manuscript (including the Title) a cause-effect relationship between chromatin looping and gene activation. They state in a subheading of the results that '*MAF1* knockdown enhanced *CDKN1A* gene expression from both long and short form promoters through Pol III-mediated promoter looping'. In the next subheading they repeat: '*MAF1* knockdown enhanced *GDF15* gene expression through PolIII-mediated promoter looping'. This is a massive misinterpretation of data, because there is no experiment showing a cause-effect relationship between looping and gene activity, only a correlation. The authors state that 'Moreover, simultaneous knockdown of *MAF1* with either Pol III or *BRF1* (subunit of TFIIIB) disrupted the looping formation ([Figure 5D-E](#fig5){ref-type="fig"}). These observations suggest chromatin looping between the long and short form promoter regions is important for the activation of *CDKN1A* transcription from both promoters', and 'The above results demonstrate that *MAF1* knockdown can activate *CDKN1A* expression through promoter looping induced by recruitment of Pol III and Pol II along with histone-modifying factors'. Later on, they state 'These results further demonstrate unambiguously that *MAF1* protein represses the promoter activity of *CDKN1A* and *GDF15*, and that recruitment of Pol III after *MAF1* depletion is crucial for the activation of transcription of these genes through promoter looping'. The looping observed may as well be a consequence, rather than a driver, of gene activation, or just as well a totally inconsequential event. The manuscript should be rewritten to remove all indication of cause-effect relationship between looping and gene activation.

4\) The authors rely on the use of a single cell line, MCF7. As these are breast cancer cells that have sustained multiple genetic alterations, it is unclear whether the findings will hold in normal cells or even in other tumor cell lines. This needs to be addressed as the results with *MAF1* may represent a peculiar result of the specific genetic make-up of this single, genetically complex cell type.

5\) The bulk of the findings rely in the use of RNAi approaches but the authors use only a single targeting sequence for the knockdown of each particular target. Multiple targeting sequences need to be used and the extent of downregulation at both the protein and RNA levels needs to be shown to reduce the possibility of off-target effects and to further validate the conclusions.

6\) As a general comment both on the cellular knockdown data and the in vitro immuno-depletion data, the authors do not generally indicate the extent of depletion of the factors of interest, and this may well account for some of the modest, albeit significant, effects. Thus it would help to have data/comments on the depletion efficiencies.

7\) In the nuclear run-on assay of [Figure 1D](#fig1){ref-type="fig"}, the effect of the *MAF1* knockdown on *CDKN1A* expression appears relatively modest (especially in relation to the clear large effect in the quantitative RT-PCR analysis of [Figure 1C](#fig1){ref-type="fig"}). Could the authors provide quantitation of the data for *CDKN1A* (and for *GDF15*, where the up-regulation is larger) and perhaps improved data?

8\) The authors state that knocking down Pol III alone did not affect *CDKN1A* expression. However, a close examination the data in [Figure 1C](#fig1){ref-type="fig"} suggest that expression of *CDKN1A* is actually reduced about 30% (and that of *GDF15* more than 50%). This fits the model that Pol III can positively regulate the expression of *CDKN1A* and *GDF15*, but is potentially inconsistent with the authors\' failure to see any Pol III occupancy prior to *MAF1* knockdown. Is this just due to the lower sensitivity and higher background in the ChIP analysis?

9\) In [Figure 3C](#fig3){ref-type="fig"}, the *MAF1* ChIP signal is only 3-fold above background. Because this data provides important evidence of direct regulation, and even though it is supported by the in vitro demonstration of direct *MAF1* binding to the SINE element, the authors might consider ways to modify the ChIP protocol to increase the signal/background ratio.

10\) While the in vitro data for the direct *MAF1* binding to the p21 SINE element ([Figure 4](#fig4){ref-type="fig"}) seems convincing, especially with the SINE deletion control, it would be very interesting to have more detailed data on the interaction site in light of the novelty of this observation. Have the authors any further information from DNase footprinting, gel shifts with point mutations in the Pol III promoter elements etc. on this point, especially in relation to their suggestion in the Discussion that "*MAF1* and Pol III/TFIIIB may recognize similar DNA elements"? (It should also be noted that the promoter elements of Pol III-transcribed genes are directly recognized by TFIIIC and not by Pol III/IIIB.)

11\) In relation to the interesting (and potentially provocative) new *MAF1* mechanism involving direct binding to promoter elements, the reader is advised (in the Introduction) of prior reports indicating *MAF1* binding to *BRF1* and/or Pol III as well as Pol III/*MAF1* co-occupancy on target genes, and thus anticipates that *MAF1* may be repressing Pol III function by a related mechanism on the target genes analyzed here. This, of course, appears not to be the mechanism from the ChIP analyses that follow the functional studies, but I think the rationale and results could be presented with more clarity and with clear indications that, perhaps surprisingly, they do not fit the original models but suggest an alternate mechanism that is pursued (by the direct binding studies).

\[Editors' note: further concerns were raised before acceptance.\]

Thank you for resubmitting your article entitled "MAF1-Regulated-Pol III-Mediated Activation of *CDKN1A* and Chromatin Looping" for further consideration by *eLife*. Your revised submission has been evaluated by the original Reviewing Editor and Senior Editor.

Despite a commendable effort by the authors to try to address the concerns raised by the reviewers, the revised manuscript fails to meet the high standards of scholarship expected for publication in *eLife*. The authors have performed additional experiments in response to the reviewers suggestions, mostly to include missing controls and replicates, but the manuscript still fails to produce a clear picture of how exactly *MAF1* and POLIII regulate protein-coding genes such as *CDKN1A* and *GDF15*.

The major issue is that, in response to a request for clarification from the reviewers, it is now evident that the genomic region that the authors have called the 'p21 long promoter' (p21L) is indeed the enhancer regulatory region of this gene, known to be bound by p53 and many other transcription factors. This region, located 2.25kb upstream of the canonical p21 promoter, produces enhancer-derived RNAs (eRNAs) and may engage with the promoter through a chromatin loop. In view of this, the entire dataset must be reinterpreted as *MAF1* and POLIII likely affecting the activity of the enhancer region at the *CDKN1A* locus, and the manuscript should be rewritten in light of this fact.

Finally, the revised manuscript failed to correct some points raised by reviewers. As an example of a major oversight, the authors tested for 'p53 activation' by Q-RT-PCR, when it is well established that p53 activation upon cellular stress occurs at the protein level, and thus should have been tested by Western blot.

10.7554/eLife.06283.015

Author response

*1) The possible role of p53. The two genes examined throughout the manuscript,* CDKN1A *and* GDF15*, are the two most potently transcribed p53 target genes (Allen et al.,* eLife *2014). However, the authors do not examine the effects that p53 may play in their system. It is entirely possible that most of the effects described upon* MAF1 *knockdown are driven indirectly by activation of p53 downstream of a cellular stress response caused by deregulated RNAPIII function. The authors should check for p53 induction upon* MAF1 *knockdown. Key experiments should be repeated in an isogenic system -/+ p53. This could be done with stable p53 knockdown MCF7 cells (Agami et al.) or HCT116 p53 -/+ cells (Vogelstein et al.)*.

We thank you for your insightful suggestion in bringing p53 to our awareness. Indeed, both *CDKN1A* and *GDF15* are p53 target genes ([@bib3]) and therefore maybe indirectly activated by p53 instead of *MAF1*. To directly address this question, we perform *MAF1* knockdown experiments in wild-type and p53-null HCT116 cells. Western blot indeed demonstrate the lack of p53 protein in p53-null HCT116 ([Figure 1--figure supplement A](#fig1s1){ref-type="fig"}; subsection headed "MAF1 knockdown strongly upregulated *CDKN1A* expression"). Since *CDKN1A* expression is induced in both of these cell lines, the induction is independent of p53 ([Figure 1--figure supplement C-D](#fig1s1){ref-type="fig"}; same section).

*2) Promoter definition. The authors indicate that 'Examination of* CDKN1A *gene shows that there are two promoter regions (hereafter referred as long and short form)'. This description contrasts with many earlier reports that clearly show a major promoter for* CDKN1A *with minor alternative start sites. What exactly are the long and short forms? What NM genebank reference numbers do they correspond to? Where are they located relative to the well-characterized p53 enhancers? Importantly, the authors show equivalent Ser5-phospho-RNAPII binding to both promoters, but high H3K4me3 and TBP binding are found only at the downstream promoter encoding the 'short form', indicating that this promoter is the functional promoter. Confusingly, although the authors show equivalent binding of Ser5-phospho-RNAPII to both promoters, RBP5, a subunit common to all three polymerases is found preferentially at the downstream promoter. How much RNA is being produced from the 'long' and 'short' promoters? Some form of quantitative assay should be done to define the relative strength and RNA output of these two 'promoters'*.

We thank you for highlighting that many earlier reports clearly show a major promoter for *CDKN1A* with minor alternative start sites. Indeed, most published papers refer to the transcription start site (TSS) of short form promoter, whereas the well-characterized p53 enhancers are located 1.4 kb and 2.3 kb upstream from TSS, which is near long form promoter (Hung et al., 2011; Lee et al., 2012). In our manuscript, the long form promoter refers to the upstream region of NM_001220777, whereas the short form promoter refers to the upstream region of NM_001220778 according to NM genebank reference numbers ([Figure 3--figure supplement A](#fig3s1){ref-type="fig"}). The relative location of the first exons of *CDKN1A* ("L-Ex-1" for long form and "Ex1" for short form) with respect to the identified p53 response elements and ChIP amplicons (p21-L, p21, p2 and p3) is depicted in [Author response image 1](#fig9){ref-type="fig"}.10.7554/eLife.06283.016Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.06283.016](10.7554/eLife.06283.016)

Therefore, we have modified the text to: "Examination of *CDKN1A* gene in the UCSC Genome Database shows that there are two transcription start sites, NM_001220777 (long form) and NM_001220778 (short form), which are 2.25 kb apart" ([Figure 3--figure supplement A](#fig3s1){ref-type="fig"}; the subsection headed "*CDKN1A* promoter"). Although the expression of both forms is induced after *MAF1* knockdown, the short form has a higher expression level and stronger promoter activity in MCF-7 cell line ([Figure 3--figure supplement B-D](#fig3s1){ref-type="fig"}; same section).

In order to show the relative strength and RNA output of the two promoters, we perform luciferase assay and quantitative RT-PCR to detect the relative promoter activity and transcription level, respectively. In consistent with short form promoter being the major promoter, our luciferase promoter assay showed that the short form *CDKN1A* has a higher promoter activity than the long form ([Figure 3--figure supplement D](#fig3s1){ref-type="fig"}). Consistent with the above result, our quantitative RT-PCR analysis also shows that the expression of the short form of *CDKN1A* is higher than the long form ([Figure 3--figure supplement B](#fig3s1){ref-type="fig"}). Since both forms of *CDKN1A* contain active promoters and are transcribed, Ser5-phospho-RNAPII is detected at both promoter regions ([Figure 3E](#fig3){ref-type="fig"} and [Figure 3--figure supplement B-D](#fig3s1){ref-type="fig"}). However, due to the fact that the short form promoter is the major promoter with higher expression level and promoter activity, the detection of H3K4me3, as well as binding of TBP and RBP5 are found preferentially at short form promoter. The weak binding of these factors on long form promoter is consistent with the lower activity of the long form promoter. However, the biological function of the long form *CDKN1A* with alternative 5′ non-coding exon remains to be elucidated.

*3) Massive misinterpretation of 'chromatin looping' data. The authors repeatedly state throughout the manuscript (including the Title) a cause-effect relationship between chromatin looping and gene activation. They state in a subheading of the results that* 'MAF1 *knockdown enhanced* CDKN1A *gene expression from both long and short form promoters through Pol III-mediated promoter looping'. In the next subheading they repeat:* 'MAF1 *knockdown enhanced* GDF15 *gene expression through PolIII-mediated promoter looping'. This is a massive misinterpretation of data, because there is no experiment showing a cause-effect relationship between looping and gene activity, only a correlation. The authors state that 'Moreover, simultaneous knockdown of* MAF1 *with either Pol III or BRF1 (subunit of TFIIIB) disrupted the looping formation (*[*Figure 5D-E*](#fig5){ref-type="fig"}*). These observations suggest chromatin looping between the long and short form promoter regions is important for the activation of* CDKN1A *transcription from both promoters', and 'The above results demonstrate that* MAF1 *knockdown can activate CDKN1A expression through promoter looping induced by recruitment of Pol III and Pol II along with histone-modifying factors'. Later on, they state 'These results further demonstrate unambiguously that* MAF1 *protein represses the promoter activity of* CDKN1A *and* GDF15*, and that recruitment of Pol III after* MAF1 *depletion is crucial for the activation of transcription of these genes through promoter looping'. The looping observed may as well be a consequence, rather than a driver, of gene activation, or just as well a totally inconsequential event. The manuscript should be rewritten to remove all indication of cause-effect relationship between looping and gene activation*.

Indeed, we have no evidence that chromatin looping plays a causal role in the gene expression of the two genes we studied. Therefore, we have rewritten the manuscript to remove the indications of cause-effect relationship between looping and gene activation. We have changed the title to "MAF1-Regulated-Pol III-Mediated Activation of *CDKN1A* and Chromatin Looping". The subheadings were also modified to "Pol III is required for transcriptional activation and chromatin looping of *CDKN1A*/*GDF15* after *MAF1* knockdown" (in the Results section).

*4) The authors rely on the use of a single cell line, MCF7. As these are breast cancer cells that have sustained multiple genetic alterations, it is unclear whether the findings will hold in normal cells or even in other tumor cell lines. This needs to be addressed as the results with* MAF1 *may represent a peculiar result of the specific genetic make-up of this single, genetically complex cell type*.

To address this question, we choose four other cell lines, MCF-10A (non-tumorigenic), MDA-MB-231, HCT116^p53+/+^ (wild-type) and HCT116^p53-/-^ (p53-null), to repeat our experiments. We performed quantitative RT-PCR to analysis the effect of *MAF1* knockdown and simultaneous knockdown of *MAF1* and *POLR3A* on the expression of *CDKN1A* and *GDF15* in these four cell lines. Consistent with the MCF-7 results, the expression of *CDKN1A* and *GDF15* is induced after *MAF1* knockdown, and simultaneous knockdown of *MAF1* and *POLR3A* abolished the induced expression ([Figure 1--figure supplement B-F](#fig1s1){ref-type="fig"}; subsection headed "*MAF1* knockdown strongly upregulated *CDKN1A* expression"). Together, these results demonstrate that *MAF1* regulates *CDKN1A* expression in non-tumorigenic (MCF-10A), as well as breast (MCF-7 and MDA-MB-231) and colon cancer (HCT116^p53+/+^ and HCT116^p53-/-^) cells, and is independent of p53.

*5) The bulk of the findings rely in the use of RNAi approaches but the authors use only a single targeting sequence for the knockdown of each particular target. Multiple targeting sequences need to be used and the extent of downregulation at both the protein and RNA levels needs to be shown to reduce the possibility of off-target effects and to further validate the conclusions*.

To address this question, we ordered two more siRNA targeting sequences for *MAF1* and *POLR3A*. Quantitative RT-PCR and western blot were performed to analyze the knockdown effect of *MAF1* and *POLR3A* using three different siRNAs, including the original one. The results showed that the three siRNAs for *MAF1* depleted *MAF1* and up-regulated tRNA genes, as well as *CDKN1A* and *GDF15* ([Figure 1A-B and D-E](#fig1){ref-type="fig"}; subsection headed "*MAF1* knockdown strongly upregulated CDKN1A expression"). However, probably due to slow turnover time of *MAF1* protein, western blot analysis showed only 45% of reduction for the *MAF1* protein in cells treated with siRNA (\#1, the one used in the original experiment) with the strongest affect. Nevertheless, the reduction percentage for *MAF1* is consistent with the up-regulation of *CDKN1A* in mRNA and protein level, indicating that depletion of *MAF1* induces *CDKN1A* expression ([Figure 1A-B and D-E](#fig1){ref-type="fig"}; in the aforementioned section). The three siRNAs for *POLR3A* also depleted *POLR3A* and down-regulated tRNA genes ([Figure 1--figure supplement G-H](#fig1s1){ref-type="fig"}; subsection headed "*MAF1* knockdown strongly upregulated *CDKN1A* expression"). The siRNAs with the strongest knockdown affect for *MAF1* (\#1, the original one) and *POLR3A* (\#1, the original one) were used to perform knockdown in ChIP, 3C and reporter assays.

*6) As a general comment both on the cellular knockdown data and the in vitro immuno-depletion data, the authors do not generally indicate the extent of depletion of the factors of interest, and this may well account for some of the modest, albeit significant, effects. Thus it would help to have data/comments on the depletion efficiencies*.

For cellular knockdown, we have performed western blot analysis to show that *MAF1* and *POLR3A* are reduced about 45% and 60% in protein level, respectively ([Figure 1B](#fig1){ref-type="fig"}; subsection "*MAF1* knockdown strongly upregulated *CDKN1A* expression" and [Figure 1--figure supplement H](#fig1s1){ref-type="fig"}). For the depletion efficiency of in vitro immune-depletion data, we used anti-Pol II antibody on Pol II genes, *CDKN1A*, *GDF15* and *TAF5*, to show that the transcription activity is reduced 93%±4%, which is similar to treatment with α-amanitin (87%±1%) ([Figure 4D-E](#fig4){ref-type="fig"}; subsection "In vitro transcription using HeLa cell nuclear extract demonstrated that transcription of Pol II genes was reciprocally regulated by *MAF1* and Pol III). We also used anti-Pol III antibody on Pol III transcribed-RPPH1 to show that the reduction is 79%±1% ([Figure 4E](#fig4){ref-type="fig"}; aforementioned subsection). The modest, albeit significant, results may thus be accounted by the depletion level.

*7) In the nuclear run-on assay of* [*Figure 1D*](#fig1){ref-type="fig"}*, the effect of the* MAF1 *knockdown on* CDKN1A *expression appears relatively modest (especially in relation to the clear large effect in the quantitative RT-PCR analysis of* [*Figure 1C*](#fig1){ref-type="fig"}*). Could the authors provide quantitation of the data for* CDKN1A *(and for* GDF15*, where the up-regulation is larger) and perhaps improved data*?

We repeated run-on assay to provide quantification results (n=3) and a more improved gel picture in [Figure 2A-B](#fig2){ref-type="fig"} (please see "*MAF1* knockdown strongly upregulated CDKN1A expression"). The gel pictures were quantified with ImageJ (provided by NIH: <http://imagej.nih.gov/ij/>). The purified run-on products where normalized with internal control (*GAPDH*) to obtain the relative transcription levels for each gene. *MAF1* knockdown induced the expression of *CDKN1A* and *GDF15* for 2.9±0.8 and 88.8±12.2 folds, respectively, in run-on assay. This shows that *MAF1* knockdown induces newly transcribed *CDKN1A* and *GDF15* mRNA, and the up-regulation is not due to post-transcriptional processing or RNA turnover rates. The run-on results were moved from [Figure 1E-F](#fig1){ref-type="fig"} to [figure 2A-B](#fig2){ref-type="fig"} for clarity.

*8) The authors state that knocking down Pol III alone did not affect* CDKN1A *expression. However, a close examination the data in* [*Figure 1C*](#fig1){ref-type="fig"} *suggest that expression of* CDKN1A *is actually reduced about 30% (and that of* GDF15 *more than 50%). This fits the model that Pol III can positively regulate the expression of* CDKN1A *and* GDF15*, but is potentially inconsistent with the authors\' failure to see any Pol III occupancy prior to* MAF1 *knockdown. Is this just due to the lower sensitivity and higher background in the ChIP analysis*?

The expression of *CDKN1A* and *GDF15* is indeed reduced about 30% and 50%, respectively, in Pol III knockdown, which fits the model that Pol III can positively regulate the expression of *CDKN1A* and *GDF15*. However, the occupancy of Pol III prior to *MAF1* knockdown is relatively very weak. Thus, we speculate that since the down-regulation of *CDKN1A* and *GDF15* is not as efficient as tRNA genes after Pol III knockdown, the amount of Pol III binding at *CDKN1A* and *GDF15* prior to *MAF1* knockdown may be too low to be differentiated from background (MAF1/Pol III knockdown). Thus, although knockdown Pol III showed a decrease in Pol III binding at tRNA genes, the amount of Pol III is relatively the same as the *CDKN1A* and *GDF15* knockdown control and MAF1/Pol III knockdown. It is possible that there is a minor subpopulation of alleles with Pol III bound at the promoter, and they are responsible for the low level background transcription. Knockdown of Pol III will thus reduce the background expression level from this subset of alleles. However, the low level of binding does not allow us to show that unequivocally. Therefore, we modify the manuscript in the Discussion to state that Pol III may be able to regulate expression of *CDKN1A* and *GDF15*, before *MAF1* knockdown, but the low level of Pol III binding prior to *MAF1* knockdown does not allow us to validate this possibility unequivocally (Discussion).

*9) In* [*Figure 3C*](#fig3){ref-type="fig"}*, the* MAF1 *ChIP signal is only 3-fold above background. Because this data provides important evidence of direct regulation, and even though it is supported by the in vitro demonstration of direct* MAF1 *binding to the SINE element, the authors might consider ways to modify the ChIP protocol to increase the signal/background ratio*.

In order to optimize our ChIP protocol, we performed pilot experiments by adding different concentrations of BSA (0, 5, 10, 20 and 50 μg/ml) during complex binding, as well as using various washing conditions (either with or without LiCl or by washing with different number of times for high-salt washing buffer). The condition used (see Methods) is already our optimized condition after testing various conditions. Our 3-fold signal/background ratio for *MAF1* ChIP is also relatively higher than other published *MAF1* ChIP data, which showed a 2-fold signal/background ratio at Pol II and Pol III promoter in yeast and mammalian cell lines (Graczyk et al., 2011 \[[Figure 4A](#fig4){ref-type="fig"}\]; [@bib18] \[[Figure 7C](#fig7){ref-type="fig"}\]; Palian et al., 2014 \[[Figure 5B](#fig5){ref-type="fig"}\]). Whether the relatively low binding in the MAF1 ChIP assay is due to the intrinsic inefficiency of MAF1 antibody available or to omission of an unknown cofactor remains to be analyzed in the future.

*10) While the in vitro data for the direct MAF1 binding to the p21 SINE element (*[*Figure 4*](#fig4){ref-type="fig"}*) seems convincing, especially with the SINE deletion control, it would be very interesting to have more detailed data on the interaction site in light of the novelty of this observation. Have the authors any further information from DNase footprinting, gel shifts with point mutations in the Pol III promoter elements etc. on this point, especially in relation to their suggestion in the Discussion that "MAF1 and Pol III/TFIIIB may recognize similar DNA elements"? (It should also be noted that the promoter elements of Pol III-transcribed genes are directly recognized by TFIIIC and not by Pol III/IIIB*.*)*

In addition to the SINE deletion control, we constructed point mutations in the A-box Pol III promoter element obtained from *CDKN1A* promoter. We performed in vitro binding assay using the A-box-mutated SINE element as described before ([@bib5]; [@bib34]) ([Figure 4B](#fig4){ref-type="fig"}; subsection "*MAF1* binds to the short interspersed element (SINE) of *CDKN1A*"). In addition, we also performed in vitro DNA-protein binding assay by using a colorimetric assay kit provided by Abcam (ab117139) to further validate that *MAF1* binds to the Pol III promoter element, but not the mutant form ([Figure 4C](#fig4){ref-type="fig"}; please also see the aforementioned subsection). We hope that the two assays along with mutant forms of Pol III promoter can provide more detailed data on the interaction site.

*11) In relation to the interesting (and potentially provocative) new* MAF1 *mechanism involving direct binding to promoter elements, the reader is advised (in the Introduction) of prior reports indicating* MAF1 *binding to BRF1 and/or Pol III as well as Pol III/*MAF1 *co-occupancy on target genes, and thus anticipates that* MAF1 *may be repressing Pol III function by a related mechanism on the target genes analyzed here. This, of course, appears not to be the mechanism from the ChIP analyses that follow the functional studies, but I think the rationale and results could be presented with more clarity and with clear indications that, perhaps surprisingly, they do not fit the original models but suggest an alternate mechanism that is pursued (by the direct binding studies)*.

We thank you for highlighting that we should modify the manuscript to present the rationale and results in more clarity and indications that our model does not fit the original models. Therefore, we have rewritten the last paragraph of the Introduction and modified the first paragraph of the Discussion to suggest an alternate mechanism as shown by the direct binding studies.

\[Editors' note: a second round of author responses follow.\]

*Despite a commendable effort by the authors to try to address the concerns raised by the reviewers, the revised manuscript fails to meet the high standards of scholarship expected for publication in* eLife*. The authors have performed additional experiments in response to the reviewers suggestions, mostly to include missing controls and replicates, but the manuscript still fails to produce a clear picture of how exactly* MAF1 *and POLIII regulate protein-coding genes such as* CDKN1A *and* GDF15*.*

Overall, this report presents some exciting new findings that are very timely in view of (i) extensive ChIPseq data in the literature demonstrating the localization of components of the Pol III transcription machinery adjacent to Pol II-transcribed genes and (ii) the widespread localization of SINE elements (of unknown function) in the human genome and near promoters". The decision is based mainly on three criticisms, which we would like to respond to here.

First, PCAF in our manuscript is *not* PCNA as stated in the rejection letter. PCAF is lysine acetyltransferase 2B (an interacting partner of the transcriptional co-integrators CBP and p300), also known as P/CAF, or KAT2B; and it has been shown to be associated with p300 for chromatin modification. We performed ChIP of PCAF to show that this epigenetic factor becomes associated with *CDKN1A* promoter after *MAF1* knockdown (subsection "*MAF1* knockdown promoted recruitment of positive regulatory factors and epigenetic modifications" and [Figure 5E](#fig5){ref-type="fig"}). Therefore, this is just a misunderstanding.

The second point is about our interpretation of our data in view of the fact the 2.25kb upstream of canonical promoter is probably the enhancer region. We will rewrite the manuscript to incorporate this fact. As Darwin said: "False facts are highly injurious to the progress of science, for they often long endure; but false views, if supported by some evidence, do little harm, as every one takes a salutary pleasure in proving their falseness". A set of data can always have different interpretation and progress of science is achieved to resolve the different hypothesis or interpretation. We will also perform experiment to test whether the upstream region is the enhancer for the canonical promoter. We will restrict the interpretation in the Discussions section, which is the place used for making hypothesis or interpretation of the data.

The third point is that we failed to correct some points raised by the reviewers such as the test of p53 level by western blot. We did not perform western blot in the revised manuscript because we have already shown that in the revised manuscript, *CDKN1A* and *GDF15* in both HCT116 and HCT116^p53-/-^ cell lines were up-regulated, and thus the effect is independent of p53. Nevertheless, we will perform western blot of p53 to further show that the up-regulation of *CDKN1A* and *GDF15* after *MAF1* knockdown is independent of p53.

*The major issue is that, in response to a request for clarification from the reviewers, it is now evident that the genomic region that the authors have called the 'p21 long promoter' (p21L) is indeed the enhancer regulatory region of this gene, known to be bound by p53 and many other transcription factors. This region, located 2.25kb upstream of the canonical p21 promoter, produces enhancer-derived RNAs (eRNAs) and may engage with the promoter through a chromatin loop. In view of this, the entire dataset must be reinterpreted as* MAF1 *and POLIII likely affecting the activity of the enhancer region at the* CDKN1A *locus, and the manuscript should be rewritten in light of this fact*.

The editors questioned the interpretation of our data in view of the fact the 2.25 kb upstream of canonical promoter is probably the enhancer region. For clarification, the TSS start site of NM_001220777 (long form *CDKN1A*) is located 2.25 kb upstream of NM_001220778 (short form *CDKN1A*) TSS. However, the chromatin looping and identified MAF1 binding site by ChIP is 2.65 kb upstream of TSS. Therefore, to address the possibility of enhancer activity at this region, we cloned the 2.25 ∼ 2.65 kb upstream region into the promoter of *CDKN1A* (CDKN1A-S) used in our original luciferase assay. The promoter activity was analyzed by luciferase assay and the results showed that the cloned 5′ region, both in sense (labeled as "LE(+)") and antisense direction (labeled as "LE(-)") does not exert enhancer activity on *CDKN1A* promoter after *MAF1* knockdown as shown below ([Author response image 2](#fig10){ref-type="fig"}). We have included the interpretation in our Discussion section, but did not include the data in the results. In brief, we hypothesized that the chromatin looping we observed for *CDKN1A* and *GDF15* after *MAF1* knockdown may be mediated through the proximity of these 5′ regions in the transcription factory and looping is resulted by the interaction between the sets of transcriptional factors recruited in the two 5′ flanking regions after chromatin remodeling as proposed by [@bib9].10.7554/eLife.06283.017Author response image 2.**DOI:** [http://dx.doi.org/10.7554/eLife.06283.017](10.7554/eLife.06283.017)

*Finally, the revised manuscript failed to correct some points raised by reviewers. As an example of a major oversight, the authors tested for 'p53 activation' by Q-RT-PCR, when it is well established that p53 activation upon cellular stress occurs at the protein level, and thus should have been tested by Western blot*.

The other concern raised by the editors is that we failed to test p53 level by western blot to determine whether the induced *CDKN1A* expression after *MAF1* knockdown is independent or dependent of p53. To directly show that induced *CDKN1A* expression after *MAF1* knockdown is independent of p53, we analyzed the *MAF1* knockdown effect of *CDKN1A* expression in p53-null HCT116. Western blot analysis indeed confirmed that this cell line does not express p53 at protein level ([Figure 1--figure supplement A](#fig1s1){ref-type="fig"}; subsection entitled "*MAF1* knockdown strongly upregulated *CDKN1A* expression"). Both quantitative RT-PCR and western blot showed that the expression of *CDKN1A* is induced after *MAF1* knockdown in p53-null HCT116 cell line ([Figure 1--figure supplement C-D](#fig1s1){ref-type="fig"}; aforementioned subsection). This result unequivocally shows that in the absence of p53 protein, the expression of *CDKN1A* is still induced after *MAF1* knockdown, indicating the induced transcription is independent of p53. Consistent with this result, we also showed that induction of *CDKN1A* expression in MDA-MB-231 cell line, which carries mutation in p53 ([Figure 1--figure supplement F](#fig1s1){ref-type="fig"}; same subsection).
